Skip to main content
International Journal of Pharmaceutics: X logoLink to International Journal of Pharmaceutics: X
. 2026 Oct 29;12:100693. doi: 10.1016/j.ijpx.2026.100693

From bench to clinic, are organoids ready for modeling drug delivery in brain disease?

Qiong Xiang a,b,⁎, Ming-Xin Zheng a,1, Jing-Ru Yuan a,1, Song-Rong Lin a,1, Xiao-Da Li c, Xian-Hui Li a,b,⁎
PMCID: PMC13744809  PMID: 43001240

Abstract

Brain diseases remain a significant challenge in the field of modern medicine. The protective function of the blood-brain barrier (BBB) also complicates drug delivery for neurological disorders. However, under certain pathological conditions, the BBB is compromised during the progression of these pathophysiological processes. To integrate with clinical treatments, precise and personalized requirements exist for basic research. Three-dimensional (3D) in vitro systems, particularly organoids, serve as valuable models for preclinical disease research. Starting from the functionality and feasibility of organoids, this review explores their potential roles and applications in brain diseases. It also discusses advanced technologies to overcome in vitro modeling challenges and their applications in evaluating therapeutic strategies and drug delivery. Moreover, with the ability to predict and rapidly screen effective drugs, organoid modeling will be valuable in accelerating the clinical translation of new therapeutics.

Keywords: Organoids, BBB, Drug delivery, Brain disease, Application

Graphical abstract

Brain diseases, still remain large challenge in modern medicine field. The protective role of the blood-brain barrier(BBB) also confounds drug delivery for brain diseases. Considering the capability and achievability of organoids, their potential ability and application in brain disease are reviewed. In parallel, with the ability to predict and rapidly screen effective drugs, organoids modeling will be valuable in accelerating the new drugs into the clinic.

Unlabelled Image

1. Introduction

Brain and central nervous system (CNS) disorders are among the clinically refractory diseases, primarily composed of endothelial cells (ECs), pericytes, and astrocytes behind the blood-brain barrier (BBB). (Saylor, 2021) Along with neurons, microglia, basement membrane, and (Crouch et al., 2023), they have long posed challenges in treatment. These components also form the neurovascular unit (NVU), influencing brain function and protecting the brain from potential harm (Fig. 1, Fig. 2). (Arvanitis et al., 2020; McConnell and Mishra, 2022) Meanwhile, the NVU supports neuronal complexes, maintains their composition, and regulates the permeability of the blood-brain barrier. Brain microvascular endothelial cells (BMVECs) in the NVU form tight junctions through interactions with astrocytes and pericytes (Garcia-Gallardo and Campbell, 2025; Vo et al., 2023), regulating ion transport between the brain parenchyma and peripheral blood (Cherubini and Haase, 2023). Astrocytes or glial cells interacting with endothelial cells may tighten the BBB by enhancing tight junction expression (Hudson and Campbell, 2021; Pfau et al., 2024a). Microglia, macrophages surrounding cerebral blood vessels, control the brain's innate and adaptive immune responses. Pericytes play a structural role in maintaining BBB function and stability, such as the expression of BBB-specific genes and the polarization of astrocytes (Zhang et al., 2024; Ronaldson and Davis, 2022). The basement membrane, an extracellular matrix (ECM) composed of collagen, fibronectin, laminin, and proteoglycans, separates the vascular system crucial for BBB normal function (Logsdon et al., 2021; Anwar et al., 2022). Due to the density and stability of the BBB, certain large particles, proteins, hydrophilic molecules, and drugs cannot bypass the BBB (Abu-Nab et al., 2025; Soler et al., 2023). However, under certain pathological conditions, BBB disruption leads to increased permeability, which is more closely associated with neurological disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), stroke, epilepsy, multiple sclerosis (MS), and even brain cancer (Lin et al., 2021; Zierfuss et al., 2024a; de Rus et al., 2023; Candelario-Jalil et al., 2022; Mohi-Ud-Din et al., 2022; Zierfuss et al., 2024b; Angom et al., 2023a); On the other hand, improving the function of the BBB in the progression of neurodegenerative diseases and the underlying mechanisms include enhancing BBB permeability and promoting its functional recovery. The BBB and its associated ECM have been demonstrated to have the potential for treating central nervous system diseases. However, the main obstacles for clinical translation, especially in terms of precise delivery, still exist.

Fig. 1.

Fig. 1

The blood-brain barrier (BBB) structure displays exhibits physical properties regulating molecular and cellular flow in the neural parenchyma. The schematic illustration was created using Biorender.com.

Fig. 2.

Fig. 2

The blood-brain barrier (BBB) and its ECM mircoenvirment. The schematic illustration was created using Biorender.com.

Considering the complexity of brain diseases and the urgent need to improve treatment strategies, the establishment of in vitro pathophysiological models is crucial for understanding disease mechanisms and future drug design, selection, and development (Hajal et al., 2022a; Campisi et al., 2021; Hajal et al., 2022b). As mentioned above, the blood-brain barrier can regulate the transport of molecules, proteins, and some smaller particles based on their size and surface characteristics to maintain brain homeostasis. For example, oxygen, ethanol, and water passively diffuse through the blood-brain barrier. Membrane transporters, such as GLUT-1 and P-glycoprotein, allow glucose and amino acids to cross the blood-brain barrier through tight junctions (Alnaqbi et al., 2023; Ozgür et al., 2022). In addition, current rodent models are costly, time-consuming, and have ethical issues (Sun et al., 2020; Xue et al., 2023). Therefore, people's interest and prospects for organoids are increasing.

In this article,we reviewed the research progress of in vitro models from advanced technologies, advantages and limitations of design, and modifications of cells to organoids. First, we have summarized experimental models that focus on the complexity of the brain and its microenvironment, as well as the challenges of modeling brain diseases. Next, we reviewed the latest applications of these models, particularly in the field of BBB drug delivery. Finally, the impact of nanoparticles on the brain was evaluated; And summarized the prospects of using these models to quickly screen clinical application therapies.

2. The recent progress in vitro models

It is widely believed that the main challenge in developing effective treatments for brain diseases is to develop models that simulate 3D in vivo conditions for preclinical research (Soliman et al., 2025; Katt and Shusta, 2020). Although several traditional cell culture systems (2D) are still widely used, they lack the interaction or crosstalk between different types of cells and components that make up the brain microenvironment (Choi et al., 2024a; Wang et al., 2020a). In addition, the two-dimensional structure has limitations in modeling BBB structures, so in some cases, such as replicating barrier integrity (Mori et al., 2024), its reliability is not high. Therefore, in vitro 3D models are rapidly developing. Here, the following content focuses on the elements and factors that affect the establishment of in vitro models.

2.1. Elements in the process of BBB modeling

The integrity of BBB is an important factor to consider in the modeling process. Tightly connected TEER, permeability, and marker proteins (Palma-Florez et al., 2023a; Zhao et al., 2022a) are key factors in evaluating barrier integrity. The typical TEER value for displaying complete blood-brain barrier function is 1800–2000 O.cm2 (Nazari et al., 2023a), with a minimum of 1500 O.cm2 (Nazari et al., 2023a) and a maximum of 8000 O.cm2 (Nazari et al., 2023a). In fact, measurements above 500 O.cm2 are also considered complete blood-brain barrier integrity (Nazari et al., 2023b). To be noted, TEER and permeability are complementary rather than interchangeable measures of BBB function. These two parameters may vary depending on the cell source, culture conditions, and measurement protocol; therefore, they should be interpreted together, and cross-study comparisons should take these variables into account. In addition, the permeability of the blood-brain barrier can be measured using fluorescein sodium (376 Da), Lucifer yellow (440 Da), sucrose (340 Da), and fluorescently labeled dextran (Ahishali and Kaya, 2021; Qi et al., 2023; Zhao et al., 2022b; Liu et al., 2021). In normal cell culture systems, Transwell can be used to detect molecules of these sizes (Misawa and Honda, 2023; Delannoy et al., 2022; Noorani et al., 2020). In addition, some small molecules, such as sucrose and dextran, can be converted into tighter barriers (Gray et al., 2020). In addition, tight junction and adhesion proteins expressed in ECs are crucial for the integrity of the blood-brain barrier. Tight junctions are typically composed of different transmembrane proteins, which are collected by ZO-1, ZO-2, ZO-3, and MAGK (Balda and Matter, 2023; Zhou, 2023). As one of the membrane drug transporters, Pgp has also been used to study the characteristics of the blood-brain barrier due to its high expression level (Uchida, 2021). Meanwhile, ECs are crucial for BBB modeling and can be obtained from various sources, such as bEnd. 3 (Kurmann et al., 2021), RBE4 (Gericke et al., 2021), and MDCK-MDR1 (Dabbagh et al., 2022). It is worth noting that species differences are reflected in the expression levels of tight junction proteins, receptors, and transporters, which may alter the characteristics of the blood-brain barrier model (Thomsen et al., 2021; Helgudóttir et al., 2024; Jezierski et al., 2023). However, compared to other cells, HUVECs are not suitable for simulating the blood-brain barrier (Merolle et al., 2020). Despite technical challenges and expensive costs, human iPSCs have the ability to update and differentiate, and have been used to induce endothelial and pericytes for blood-brain barrier modeling properties (Valadez-Barba et al., 2020; Workman and Svendsen, 2020), exhibiting highly expressed tight junction proteins and transporters, as well as permeation efficiency close to in vivo states (Tzng et al., 2025; Stanton et al., 2025). In fact, ECs derived from iPSC can be applied to two-dimensional systems, but their potential in three-dimensional models still exists. Additionally, due to the three-dimensional complexity of the brain and blood-brain barrier, as well as the presence of various types of cells, modeling them presents significant challenges (Yan et al., 2021a). As mentioned earlier, NVU is mainly composed of neurons and glial cells, including astrocytes, microglia, oligodendrocytes, and ependymal cells (Nahon et al., 2024a). Astrocytes and pericytes jointly mediate the survival and growth of neurons, support endothelial cells, and maintain brain homeostasis (Zheng et al., 2020). Some models use single cultivation of EC, but lack the interaction between EC and NVU (Xiao et al., 2020). However, primary ECs and some immortalized ECs exhibit barrier leakage due to low expression levels of tight junction proteins and transporters (Rawat and Morrison, 2021; Ubogu, 2020). In fact, the intercellular interactions and crosstalk within the neurovascular unit (NVU) have been accepted as an important mechanism for the formation and regulation of the BBB (Boric et al., 2021; Mai-Morente et al., 2025).Moreover, the NVU can interact with the ECM and exist in a microenvironmental form. Moreover, the cellular signals emitted by the microenvironment can affect gene expression and cell state, thereby enhancing signal transduction and promoting interaction. Furthermore, the dynamic communication between ECs and the NVU is crucial for the formation and maintenance of brain functions during normal developmental stages and throughout the entire life cycle. The neural signals emitted by the microenvironment can also influence the gene expression of neurons and the cell state of ECs.

In the modeling process, the combined cell types will be more similar to generate key cell interactions. Therefore, co-culturing key components of NVU can better approach the physiological characteristics of the BBB (Robert et al., 2020; Yan et al., 2021b).

2.2. BBB models in vitro

Up to now, the mainly three types of BBB models in vitro have already emerged and have been widely applied, and there are transwell; spheroid and organoid basis; as well as microfluidics (Fig. 3). Transwell has been proven to be applied for brain delivery (Ouyang et al., 2024; Kim et al., 2023). A typical transwell system has two chambers separated by a porous membrane (Kęska, 2023), with endothelial cells growing in the upper part of the chamber (lumen or top), while astrocytes and/or pericytes grow in the lower part of the membrane (Koh and Hagiwara, 2024a) (Fig. 4). Obviously, in the Transwall model, TEER measures permeability, and due to the differences between cell culture and normal brain tissue, the values of TEER in vivo are different (Vigh et al., 2021).The BBB model was established by Transwell using monolayer cultured ECs (Chaulagain et al., 2023). Then, the model can be modified to increase barrier function by adding culture medium containing astrocytes or ECM containing glial cells (Yarygin et al., 2021; Bickel et al., 2023). In addition, to simulate physiological conditions, primary hbmec has been co cultured with astrocytes to measure the permeability of the blood-brain barrier (Liu et al., 2024). So far, Transwell has developed the BBB model composed of hbmec and nerve cells, enhancing the integrity of the BBB, regenerating NVUs with neurons, producing VEGF, and thereby affecting barrier features (Kadry and Cucullo, 2024). On the other hand, as mentioned earlier, primary ECs are difficult to obtain and have a limited lifespan; Therefore, taking hCMEC/D3 as an example, it is widely used (Monteiro et al., 2024) and exhibits BBB characteristics (Mishra et al., 2024). Since the defects of hCMEC/D3, research has been conducted on hiPSCs (Nahon et al., 2024b). For instance, the measurement of BBB features based on the Transwell model shows that hipposc derived brains co located in the cell interaction region exhibit higher TEER values; After co-culturing with astrocytes, both TEER values and permeability increased (Singh et al., 2024; Yan et al., 2021c). Quantitative and reliable methods to obtain the expression of ZO-1 and Pgp, as well as heavier glucans (>70 kDa), would be very beneficial. Li et al.’s research shows that, hiPSC-ECs, Co culture of pericytes, astrocytes, and neural stem cells derived from Hipsc can significantly improve the functional characteristics of the blood-brain barrier (Li et al., 2022). In addition, co-culturing multiple types of cells or using hipsc can improve the Transwell model (Bull et al., 2022; Lee et al., 2020). Meanwhile, the modification of TEER will characterize the 3D blood-brain barrier model, thereby improving the high-throughput and potential translational applicability of these systems between 2D and in vivo testing (Song et al., 2024).

Fig. 3.

Fig. 3

Classification of in vitro BBB models. A Transwell models are commonly used. B. BBB spheroids are generated by endothelial cells, pericytes, and astrocytes in culture vessel. C A microfluidic model with a 2D Transwell-like design, consists of a porous membrane sandwiched between two or more channels. D 3D hydrogel-laden microfluidics platform to form a microvascular network. The schematic illustration was created using BioRender.

Fig. 4.

Fig. 4

Modified BBB in vitro model based on Transwell. A. (1) A detailed schematic illustration of (a) the annular shaking dish (AS) and (b) the culture protocol for the AS BBB model. (2)The optimization of the BBB 24-transwell model using the trans-endothelial electrical resistance (TEER) value and %lucifer yellow (LY) diffusion. (3) The annular shaking dish (AS) size effect on the (a) trans-endothelial electrical resistance (TEER), (b) %lucifer yellow (LY) diffusion, and (c) rhodamine 123 (P-gp substrate) efflux ratio. (4) The mRNA expression levels of CLDN5 (a), OCLN (b), and CDH5 (c) with the annular shaking dish (AS) model and the Efflux ratios for (a) rhodamine 123 and (b) dantrolene were determined with and without inhibitors, where 10 μM cyclosporin and 1 μM Ko143 were employed as P-gp and BCRP inhibitors, respectively. (5) sured Blood-Brain barrier (BBB) permeability (Papp, AP to BL) of various drugs using an in vitro AS BBB model.Reproduced under terms of the CC-BY license (Kim et al., 2023), © 2023 by the authors. Licensee MDPI, Basel, Switzerland.

(B) (1) IntegrationofmultipleTissue-in-a-CUBEs for multi-tissue interaction. (2)Tight junctions of BBB-in-a-CUBE. a Immunofluorescence staining of the tight junction proteins claudin 5 (CLDN) and zonula occludens-1 (ZO-1) with von Willebrand Factor (vWF) marking the BMECs. Scalebar =50 μm. b mRNA expression levels of ZO-1, CLDN5, occludin (OCLN), and junctional adhesion molecule (JAM-A) by RT-qPCR.Expressionlevelswerenormalized tothatofCD31. Blue = Day 2, Orange = Day 4, and Yellow = Day 6. c Measurement of trans endothelial electrical resistance (TEER) as a representation of the strength of BBB tight junction showed increasing TEER values over 6 days of BBB-in-a-CUBE culture, indicating strongerbarrierformation.d The apparent permeability(Papp)of the BBB-in-a-CUBE to small hydrophilic molecule Lucifer Yellow (LY) decreased overthe course of 6 days of culture, confirming the strengthening of tight junction function. Blue = Day 2,Purple = Day4,andYellow = Day6.e The much higher Papp values obtained when the LY permeability experiment was performed using Matrigel without any cells confirmed that the low Papp values were not due to accumulation of LY in Matrigel. (3) Transporters of BBB-in-a-CUBE. a Immunofluorescence staining of the transporters multidrug resistance protein 1 (MDR1/PGP/ABCB1), multidrug resistance-associated protein 1 (MRP1/ABCC1), breast cancer resistance protein (BCRP/ABCG2), glucose transporter 1 (GLUT1/SLC2A1), large amino acid trans porter 1(LAT1/SLC7A5),monocarboxylatetransporter(MCT1/SLC16A1),organicanion transporter (OAT3/SLC22A8), and serotonin (SERT) with von Willebrand Factor (vWF)marking theBMECs.b RT-qPCR confirmed the mRNA expressions of MDR1, MRP1, BCRP, GLUT1, LAT1, MCT1, OAT3,andaquaporin4(AQP4).Expressionlevelswerenormalized tothat ofCD31. Blue = Day 2, Orange = Day 4, and Yellow = Day 6. Reproduced under terms of the CC-BY license (Koh and Hagiwara, 2024a),© 2024 by the authors.Open Access. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Although traditional 2D cultures are easy to manage and operate, they cannot present the main characteristics of BBB, 3D cell tissue, appropriate cell differentiation, localization and polarization, and cell contact (Piantino et al., 2021). As one of the most popular 3D culture systems, spheres have evolved to reshape complex cell-cell interactions (Serras et al., 2021). Spheroids are microscale spherical cell clusters that can form through self-assembly (Zhu et al., 2024; Wang et al., 2021). The sphere model has been applied in therapeutic research for evaluating drug sensitivity and resistance, as well as high-throughput drug screening (Hwang et al., 2021; Struth et al., 2024). Organoids are considered as clusters of cells in 3D systems (Tang et al., 2022), ESCs, or iPSCs, which possess self-assembly ability and exhibit features and functional capabilities similar to primitive tissues (Oldak et al., 2023; Okano and Morimoto, 2022). Typically, organoids composed of ESCs or iPSCs consist of several types of cells that are formed based on the development of their original organs (Rauth et al., 2021). The earliest established adult stem cell and iPSC organoids were brain organoids (Castiglione et al., 2022a). Generally speaking, different components and culture conditions are continuously applied to human iPSCs to simulate developmental stages until they aggregate and ultimately assemble into organoids (Pierson Smela et al., 2023; Wang et al., 2023; Fertan et al., 2024).

In order to complete the formation of 3D space, organoids are provided with supporting matrices, such as matrix gel, which is conducive to the development of brain epithelium (Kim et al., 2022). In addition to matrix or other ECM proteins, agitation applications can also help improve cell survival and tissue maturation (Castiglione et al., 2022b; Chen et al., 2023). In this case, 3D organoids are complex modeling systems that closely resemble physiological conditions and can serve as powerful systems/platforms for studying human related diseases and developing new drugs. As already known that the main challenge of culturing blood-brain barrier models in vitro is the ability of endothelial cells to spontaneously differentiate, and their characteristics may also be lost during the transition from primary conditions to subsequent growth processes (Girard et al., 2023). Meanwhile, ECs lack the expression of key blood-brain barrier regulatory factors, leading to barrier function leakage when obtaining more universal phenotypes (Rosowski et al., 2023). Obviously, researchers have established a multicellular spheroid model composed of endothelial cells, pericytes, and astrocytes (Aye et al., 2024; Choi et al., 2024b). These cells self assemble and form spheres without scaffold support; In addition, these three types of cells directly interact with each other to maintain the integrity and function of the blood-brain barrier (Pfau et al., 2024b) (Fig. 5). The 3D droplet method was used for sphere formation and compared with cells grown in the matrix (Zhang et al., 2019). Pericytes are arranged along the EC tube, either directly through intercellular contact or in close proximity. In these models, astrocytes only interact with EC tubules through the promoting effect of pericytes (Watanabe et al., 2021). In summary, the sphere model can summarize the complex 3D arrangement and intercellular interactions of various cell types in the BBB. For example, Kitamura et al. established a human conditional hiMCS BBB model on culture wells, where HASTR/ci35 (astrocytes) and HBPC/ci37 (pericytes) self assemble to form spherical nuclei, which are then covered with HBMEC/ci18 (brain microvascular endothelial cells) (Fig. 6) (Hori et al., 2024). Immunocytochemical results showed that multiple cell connected and enriched blood-brain barrier transporter genes were expressed in the spherical model HBMEC/ci18 cells. The hiMCS BBB model has a barrier function for the penetration of glucan (5 and 70 kDa) and rhodamine 123 (p-glycoprotein substrate) into the core. In addition, 2- (N - [7-nitrophenyl-2-oxo-1,3-dizol-4-yl] amino) -2-deoxyglucose (2-nbdg) showed fluorescence glucose simulated uptake in the hiMCS-BBB model. In addition, treatment with tumor necrosis factor alpha can induce inflammatory response in HBMEC/ci18 cells, indicating that blood-brain barrier inflammation can be reproduced in the hiMCS blood-brain barrier model. The formation of this sphere is similar to the results of Isogai et al. (Isogai et al., 2022). Neurospheres are generated by Muzzi et al. by controlling cell composition and can be used for functional research studies. Neurospheres grow and transfer to Mea in free culture, exhibiting functional activity that can be regulated by chemistry and electricity [126, Fig. 7]. Of course, the 3D in vitro model of the sphere has the advantages of universality and high-throughput in drug screening. However, the system appears to come from cell sources of different species, which may affect the characteristics of the BBB, and there is still insufficient confidence in the transport of drugs around the BBB in clinic.

Fig. 5.

Fig. 5

Modified spheroid model for brain delivery. A.(1) Morphological and functional differences of the vasculature between the ME and cortex. Single ECs were labeled by a single low-dose injection of 4OH-tamoxifen in adult Cdh5-CreER:Ai14 mice 1 week before analysis. Immunostaining for CD31 (red), mural cell marker PDGFRβ (white) and astrocyte endfoot marker aquaporin 4 (AQP4, green) in cortex (left) and ME (right), Reproduced under terms of the CC-BY license (Pfau et al., 2024b)© 2024. The Author(s).Open Access. (B) (1) Formation of keloid spheroids using different ratios of ATCC keloid fibroblasts and HUVECs. (2)Cell viability assay of keloid spheroids using alive cell staining with calcein AM and a dead cell staining with propidium iodide (3) Formation of keloid spheroids using patient-derived keloid fibroblasts and HUVECs at different cellular ratios.(4) Quantification with real-time PCR, Reproduced under terms of the CC-BY license (Choi et al., 2024b), © 2024 by the Author(s). Open Access. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Fig. 6.

Fig. 6

Generation and application of spheroid model. (1) Generation of apical-out spherical trophoblast organoids. (2) ST/HUVEC co-culture barrier models and translocation of drugs. Reproduced under terms of the CC-BY license (Hori et al., 2024) © 2024 by the Author(s). Open Acess.

Fig. 7.

Fig. 7

Development of neurospheroids-BBB Model. A Overview of the differentiation steps and experimental design. (1) Images of different neurospheroids in the free culture during development. The first row shows pictures obtained at DIV 40 and second row at DIV 62. Scale bar, 200 m. (2) Neuronal connectivity in neurospheroids, Reproduced under terms of the CC-BY license (Muzzi et al., 2023), © 2023 by the authors.Licensee MDPI, Basel, Switzerland.

In recent years, microfluidic devices have been widely used for cell monitoring under certain physiological conditions (Vetter et al., 2025). The improved microfluidic device combines intercellular interactions, ECM and its contacting components, as well as fluid flow related to the blood-brain barrier (Marino et al., 2023). For example, microfluidic systems have been applied to cultivate various types of cells under physiological flow conditions (Harding et al., 2022). In recent years, “on-chip organs” based on microfluidic technology have been developed (Kawakita et al., 2022; Choi et al., 2023). In fact, microfluidic blood-brain barrier chips are a dynamic model with shear stress and support for neural tissue culture (Yan et al., 2021d). Most importantly, shear stress affects cellular characteristics and functions, improves the expression of tight junction proteins, and enhances the integrity of the barrier (Andjelkovic et al., 2020). However, the limitations of microfluidic BBB models do not apply to the simultaneous screening of different drugs or concentrations for drug therapy (Musafargani et al., 2020).The sandwich microfluidic BBB model based on Transwell consists of three walls, with the bottom made of matrix or tissue culture plastic (Singh et al., 2019). Otherwise, the bottom wall will be replaced by a porous membrane (Palma-Florez et al., 2023b; Gelat et al., 2022). In the sandwich microfluidic BBB, endothelial cells are located in the upper channel and brain cells are located in the lower channel. The BBB function was measured using a microfluidic platform designed based on Transwell (Shin et al., 2019; Shin and Kim, 2022; Nelson et al., 2021) (Fig. 8).Moreover, there are also multi-layer microfluidic devices that sandwich PC films between PDMS substrates and embedding layers (Koh and Hagiwara, 2024b). Wevers et al. designed and developed a human NVU chip model, which consists of perfused blood vessels co-cultured with primary human brain endothelial cells, astrocytes derived from induced pluripotent stem cells, and neurons. Based on this model, they simulated ischemic stroke with chemical hypoxia, hypoglycemia, and perfusion arrest (Wevers et al., 2021). Due to the lack of cell interactions and microvascular systems in the Transwell model of the BBB, various microfluidic designs have been developed to simulate the BBB microenvironment (Chen et al., 2020a) (Fig. 9). Lee et al. developed a modified model that combines the advantages of 3D and microfluidic systems. This microfluidic based 3D three culture system can compare and study how peripheral blood-brain barrier related cells affect cerebral angiogenesis. In addition, the project can perfuse the vascular system and quantitatively analyze barrier functions, such as the efflux transport system (Lee et al., 2022). Although species specificity affects BBB characteristics, hCMEC/D3 is widely accepted in the formation of BBB models. Huvec has also been chosen for microfluidic devices that can not generate sufficiently tight barriers in BBB modeling (Watanabe and Sudo, 2021). Recently, ECs from hiPSCs have been used to enhance barrier sealing after co-culturing with astrocytes (Hollmann et al., 2017; Shuchat et al., 2022) (Fig. 10). At the same time, there are also some other microfluidic BBB models that introduce ECM to promote basement membrane as well as culturing cells into hydrogel coated channels/pores or collagen or fibrin hydrogel premixed cells (Alves et al., 2023; Sood et al., 2022; Yu et al., 2020; Lam et al., 2020) (Table 1, Table 2), which highlights the importance of optimizing seeding parameters and comprehensive 3D culture characterization for understanding the neurophysiological responses of these 3D systems.

Fig. 8.

Fig. 8

microfluidic platforms-BBB Model. (A)The fabrication process of a gut-on-a-chip and a hybrid chip. (B) Characterization of 3D epithelial morphogenesis in a Transwell-insertable hybrid chip. Reproduced under terms of the CC-BY license (Shin et al., 2019), © by the authors. Open Acess. (C) A workflow to induce in vitro intestinal morphogenesis. Reprints and permissions information is available at www.nature.com/reprints. (Shin and Kim, 2022).(D) Characterization of a microfluidic human gut-chip model. Reproduced under terms of the CC-BY license (Nelson et al., 2021), © 2021 by the authors. Open Acess.

Fig. 9.

Fig. 9

Microfluidic platforms for in vitro modeling of the biomimetic BBB, A Microfluidic BBB (uBBB), Reproduced under terms of the CC-BY license (Koh and Hagiwara, 2024b), ©2024 by the Author(s). (B) Brain endothelial cells, astrocytes, and neurons in a 3D NVU on-a-chip.(C) NVUs on-chips are leak-tight for small molecule sodium fluorescein and allow study of compound-induced barrier disruption.(D) In vitro BBB models. Reproduced under terms of the CC-BY license (Wevers et al., 2021), © 2021 by the Author(s).Open Acess.

Fig. 10.

Fig. 10

microfluidic platforms-BBB Model. A. (1) Differentiation of iPSCs to BMECs. iPSCs were seeded at defined densities and differentiated for either 6 days in unconditioned medium (UM) or for 4 days in defined E6 medium. Impure immature BMECs were subsequently treated for 2 days with endothelial cell (EC) medium sup plemented with bFGF and retinoic acid (RA). Mature BMECs were purified onto Transwell filters or plates for 24 h in EC medium supplemented with bFGF and RA. (2)Immunocytochemical analysis of BBB markers before and after purification.(3) E6-derived BMECs and UM-derived BMECs demonstrate equivalent efflux transporter activity. E6-derived BMECs and UM-derived BMECs were incubated with rhodamine 123 (R123) or H2DCFDA in the presence and absence of efflux transporter inhibitors, PSC833 and MK-571, respectively.(4)E6-derived BMECs respond to inductive cues from astrocytes and pericytes. Reproduced under terms of the CC-BY license (Hollmann et al., 2017),Copyright by the authors. Open Acess. B. (1)Types of organ-on-a-chip models. (2) Methods to create tubular structures in organ-on-a-chip models.(3)Methods of bioprinting.Reproduced under terms of the CC-BY license (Shuchat et al., 2022) © 2022 by the authors.Licensee MDPI, Basel, Switzerland. Open Acess.

Table 1.

Summary of the microfluidic BBB models.

Designed methods Cell Type Features Ref.
Organoplate
parallel
Human induced
pluripotent stem cells
(hiPSCs) BMECs
Highest in vitro TEER value reported to date(6635 ± 315 Ω cm2);
applicable for supporting long-term stability of BMECs harboring biallelic PARK2 mutations associated with Parkinson's Disease
(Watanabe and Sudo, 2021; Hollmann et al., 2017)
Fibrin matrix-
based structure
Primary human BECs,
pericytes, and astrocytes
Microvessels developed in flow culture;
increased astrocyte coverage and intensity of basal lamina proteins, collagen IV and laminin;the enhanced barrier function of brain microvessels
(Shuchat et al., 2022)
Organoplate
parallel
Human vasculature
tri-cultured with
pericytes and astrocytes
BBB-on-a-chip model with 3D perfusable human vasculature tri-cultured with pericytes and astrocytes; mimicking angiogenic sprouting (Lee et al., 2022)
Collagen hydrogel Primary rat brain
endothelial cells
High level expression of tight junction proteins;
formed a tight endothelial barrier layer
(Yu et al., 2020)
ECM-Collagen gels Primary rat neurons Increased cell viability of neurons long-term;
heterogeneous distribution was observed in cultures with 1 × 107 cells/mL or in the absence of CO2
(Lam et al., 2020)
Poly(methyl methacrylate)
(PMMA) sandwich
bEnd.3 cells Testing the effect of flow on targeting and penetration of nanoparticles;
investigation on the ability of a membranotropic peptide, across the BBB in different flow conditions
(Singh et al., 2019; Palma-Florez et al., 2023b)

Table 2.

Summary of the BBB models.

Type Methods Advantages Limits Application
2D models
Transwell
Co-culture in Transwell chambers (ECs, astrocytes and pericytes) Easy to operate, high throughput
The TEER value can be measured
Drug permeability screening and study on the mechanism of tight junction proteins
3D models-
Spheroid/Organoid
Self assemble three types of cells into BBB spheres 3D structure,
the cell polarity is similar to the body
Co-culture interaction mechanism and angiogenesis research
Microfluidic chip Organ-on-a-chip simulates vascular chambers and brain parenchymal chambers through microchannels Dynamic perfusion, application of fluid shear force, real-time imaging capability Dynamic changes of the BBB under the simulated inflammatory cycle
iPSC models
Organoid
Patient iPSC derived
brain microvascular endothelial cells (iBMECs)
Keep the patient's genetic background and highly simulate the characteristics of the human BBB (with a high TEER value) Immature cells, high cost Individualized pathological mechanism research, genetic neurodegenerative diseases

2.3. Summary

Taken together, the BBB model based on Transwell is widely popular due to its ease of management, low cost, and effective control of working conditions. Meanwhile, Transwell's multifunctional features are suitable for high-throughput screening of drug selection. However, these 2D systems cannot simulate the 3D features of the blood-brain barrier well, nor can they display the intercellular interactions that exhibit blood-brain barrier function. Therefore, improved or enhanced 3D systems can be used to detect the complex structure, physiological characteristics, flow dynamics, and ECM of the blood-brain barrier. Taken together, a sphere is a relatively simple 3D cellular aggregate, typically lacking the organ-specific spatial organization. Brain organoids are self-organized stem cell-derived 3D tissues that encompass the key aspects of brain development and structure. BBB/NVU organoids are specialized brain organoids or micro-tissue models designed to simulate the blood-brain barrier and the neurovascular unit, usually including endothelial cells, pericytes, astrocytes, and neurons. Chip-based organ models are microfluidic platforms that can combine cells, spheres, or organoids to recreate tissue interfaces, fluid flow, and mechanical cues. Therefore, spheres and organoids are biological model systems, while chip-based organs represent an engineering platform; BBB/NVU organoids represent a special application in the field of organoids.

To be honest, most traditional brain organoids cannot replicate fully functional NVUs. They usually lack an intact vascular network for perfusion, may contain very few or no endothelial and pericyte cells, while astrocytes are often present but remain immature and do not consistently integrate into the surrounding vascular structure. The complete basement membrane and appropriate barrier properties - such as functional tight junctions, low paracellular permeability, mature efflux transporter expression, and physiological TEER are also frequently absent. Therefore, traditional brain organoids alone cannot fully simulate the BBB function or reliably predict drug delivery in brain parenchyma. These limitations highlight the need for vascularized brain organoids, BBB/NVU organoids, and organ systems on chips, which combine endothelial cells, pericytes, astrocytes, basement membrane components, fluid flow, and validated barrier analysis. Although a multi sphere model simulating cell-cell interactions has been established, they still lack the complex of the brain microenvironment due to the lack of NVU, vascular system, and ECM. In addition, the TEER value of the sphere is not easy to evaluate. The complex cellular network generated in brain organoids leads to more intercellular communication and three-dimensional structures, as well as the environment of the brain. Microfluidic systems have many advantages in modeling the blood-brain barrier, including their ability to combine various cell types to simulate intercellular interactions and shear stress. We further acknowledge that the maturity of organoids, cell heterogeneity, batch-to-batch variability, and reproducibility remain significant challenges for translational applications. Brain organoids and BBB/NVU models typically exhibit incomplete maturation and variable cell composition. Differences in differentiation protocols, culture conditions, and measurement readings can lead to batch-to-batch variations. These factors may affect the reproducibility of barrier function measurements, including TEER and permeability. Therefore, standardized maturity criteria, comprehensive cell characteristics, and robust quality control indicators are crucial for enhancing reproducibility and promoting the translation of organoid models. On the other side, the variability in the size, cell composition, regional characteristics, maturity and differentiation efficiency of organoids remains a major obstacle in drug screening. Therefore, quality control markers should include general parameters, neural and glial markers (MAP2, GFAP, OLIG2, IBA1), as well as BBB/NVU markers (CD31, PDGFRβ, claudin-5, ZO-1, P-gp). Pre-determined standardized acceptance criteria should be established, including size, survival rate, cell composition, regional characteristics, maturity, differentiation efficiency and barrier characteristics. Standardization protocols, batch records and multi-batch validations are of crucial importance. Additionally, advanced analytical techniques, such as single-cell RNA sequencing, spatial transcriptomics, proteomics, electrophysiology, live cell imaging, and high-content screening, are of great value for verifying the identity of organoids and treatment responses. scRNA-seq and spatial transcriptomics define cell composition and regional characteristics; proteomics measures changes in protein levels; electrophysiology assesses neuronal function; live cell imaging captures dynamic responses; and high-content screening can conduct multiple phenotypic evaluations. These tools should complement standard quality control indicators and functional barrier analyses, such as TEER and permeability. However, the establishment of these models is very complex and has limitations in high-throughput screening. Finally, so far, all models have mainly focused on reproducing the elements of BBB. However, it is widely believed that organoids have the ability to mimic organ development. Otherwise, brain cancer can actually alter the blood-brain barrier, leading to significant differences in BBB function compared to the adjacent brain tumor microenvironment (Upton et al., 2022; Mokoena et al., 2025).

3. The BBB modeling application in research studies

3.1. The BBB modeling in tumor studies

Establishing a brain cancer model is not only of great significance for understanding its potential mechanisms, but also for testing new therapies with clinical significance (Wen et al., 2023a). However, the increasing complexity of the brain and tumor microenvironment hinders the development of effective treatment methods for brain cancer (Mármol et al., 2023; Blanchard and Adjei, 2023; Du et al., 2022). As the tumor develops, tight connections allow larger and excluded particles to cross the blood-brain barrier (Xu et al., 2024). Although the permeability of the BBB can be utilized to improve treatment efficacy, its uneven permeability and perfusion cannot fully determine the accumulation of drugs in brain tumors (Angom et al., 2023b) (Fig. 11). In fact, the overall tumor burden of most glioblastomas is a complete BBB, indicating that limited drug efficacy is due to insufficient distribution of drugs in brain tumors (Madani et al., 2024). For example, DIPG is a high-grade glioma in children characterized by brainstem infiltrative tumors, which does not impair the integrity of the blood-brain barrier but increases the challenge of drug delivery within the brain (Perrone et al., 2021; Chen et al., 2020b). Therefore, this further emphasizes the importance of dissecting glioma cell behavior and tumor microenvironment, and once again emphasizes the importance of establishing in vitro preclinical brain cancer models (Pasupuleti et al., 2024). The organoids derived from tumor patients provide a pathway for modeling brain tumor structures, ECM, TME, and other related parameters. Especially based on the patient derived glioblastoma organoid, it has a three-dimensional structural organization that preserves tumor microenvironment related cells such as intercellular interactions, ECM components, and blood vessels (Jacob et al., 2020). By implanting the brains of immunodeficient animals, these organs can be further expanded in vivo, known as patient derived in situ xenotransplantation, and produce organoids similar to those of patient derived organoids (Pizzocri et al., 2021). At present, organoids are useful preclinical tools for glioblastoma and drug screening, but the lack of vascular system and BBB still needs to be overcome.

Fig. 11.

Fig. 11

The tumor microenvironment (TME) of BBB. Generally, glioblastoma tumors are composed of various other cell types, including endothelial cells, pericytes, astrocytes, and immune cells, which provide support for the tumor microenvironment. TME is also composed of ECM containing hyaluronic acid, collagen, proteoglycans, and other proteins that transmit mechanical and biochemical information to tumor cells. In addition, TME is related to the tumor interstitial fluid pressure generated by ECM mechanics and cell matrix interactions.The schematic illustration was created using Biorender.com.

As mentioned above, glioblastoma tumor cells generally tend to interact with components of the brain microenvironment (Erices et al., 2023), forming cancer tails that penetrate deep into cortical material (Hasan et al., 2024), and rarely metastasize within or outside the brain (Lee and Yoon, 2023). As is well known, the brain microenvironment (TME) contains several types of cells that form a protective BBB, as well as immune cells (Zhao et al., 2022c); Therefore, the complexity of TME and its contact with tumor cells are key factors in establishing and developing glioblastoma models (Kondapaneni et al., 2024a; Cui et al., 2023).As also known that glioblastoma is a common and highly invasive brain tumor, however, it rarely metastasizes outside of the brain (Erices et al., 2023; Hasan et al., 2024; Lee and Yoon, 2023). Glioma cells can invade the brain parenchyma along blood vessels and myelin axons (Hasan et al., 2024; Lee and Yoon, 2023; Zhao et al., 2022c; Kondapaneni et al., 2024a; Cui et al., 2023; Lah et al., 2020a), resulting in basement membrane degrading and ECM remodelling (Semyachkina-Glushkovskaya et al., 2022; Khoonkari et al., 2022). Generally, the main characteristic of glioblastoma invasion is the increased proliferation and growth of the tumors, resulting in hypoxia and/or the formation of necrotic cores and pseudoprotrusions (Lah et al., 2020b; Ye et al., 2022). Additionally, simulating the invasion of glioblastoma is difficult for its rapidly behavior changing based on the extra-stimulis from microenvironment (Cantidio et al., 2022). 3D spheroid invasion is common in glioma studies as its showing cells interactions and spatial organizations (Wen et al., 2023b; Yadav and Purow, 2024). Combined the spheroid with astrocyte scaffold, providing an optional approach for exploring the invasion of glioma tumor cells (Khosla et al., 2020; Andrade Mier et al., 2023). In brief, astrocyte formed a dense multicellular network, forming a 3D scaffold rich in ECM, providing support for glioma cell invasion (Yao et al., 2020; Hausmann et al., 2023). On the contrary, microfluidic devices equipped with microchannels can accurately monitor the diffusion of individual tumor cells through brain tissue gaps (Prahl et al., 2020). The advantage of microfluidic devices is that they can capture the interaction between tumor cells and ECM, and use hydrogel scaffolds with different stiffness gradients to study the behavior of glioma cells (Kondapaneni et al., 2024b). One of the prominent features of glioblastoma is the formed pseudoprotrusions, featured by a high cell area around the necrotic core where tumor cells located, secreted pro-angiogenic factors and new blood vessels generated (Basheer et al., 2021; Lucero et al., 2020). Although this chaotic neovascularization system provides nutrients and oxygen, these vessels often leak and ECs are loosely connected, resulting in more hypoxic areas and microvascular proliferation (Wirsching et al., 2021; Mazurskyy and Howitt, 2021). To be noted, Shi et al. have already constructed glioma microfluidic chip model to measure the efficacy of the drugs (Shi et al., 2023). Meanwhile, Pun et al. combined microfluidic platform combining extrusion bioprinting and stereolithography (SLA) to generated a GlioFlow3D, which primary human cells and glioblastoma (GBM) lines were integrated into hydrogel microchannels to simulate vascular systems within the framework of SLA resin using low-cost materials (Pun et al., 2024; Tang et al., 2021). In fact, brain cancer presents additional challenges. In case of brain tumor cells, the physiological behavior of the BBB changes, damaging its integrity and leading to vascular leakage (Verma et al., 2025; Ryu et al., 2023).

Despite the leakage of BBB, the efflux transporters increased and continued to hinder the drug bypass the BBB (Liang et al., 2023; Thombre et al., 2023). Therefore, Microfluidic models have been shown to be more suitable for detecting the behavior of tumor cells and interactions with other cells (Santillán-Cortez et al., 2024). However, in these models, using ECs, to represent the BBB is very simplified. Moreover, including astrocytes or pericytes, both of which affect the characteristics of the BBB, may have greater biological relevance to EC- tumor cells interaction, although such models have not yet been implemented and tested (Lim et al., 2024; Wang et al., 2020b). Athough there is still space to improve the in vitro BBB model, the current progress provides some promising models for screening therapeutic drugs (Farshbaf et al., 2022; Deligne et al., 2020).

3.2. The BBB modeling in neurodegenerative disease studies

As already discussed above, there is already evidence indicating that diseases such as AD, PD, ALS, and brain cancer exhibit weakened BBB function and degeneration of ECs (Lin et al., 2021; Zierfuss et al., 2024a; de Rus et al., 2023; Candelario-Jalil et al., 2022; Mohi-Ud-Din et al., 2022; Zierfuss et al., 2024b; Angom et al., 2023a). The occurrence of BBB dysfunction is accompanied by dysfunction of the neurovascular system, loss of neuronal function, and neuroinflammatory responses. It is particularly noteworthy that vascular injury can also be observed in tissue samples from patients and animals with chronic psychological disorders. In this condition, the vascular perivascular microenvironment undergoes changes, manifested as thickening of the basement membrane, deformation of astrocyte foot processes, activation of microglia, and chronic neuroinflammatory responses. With the alteration of the BBB microenvironment, secondary pathological changes will develop, and the process of drug entry into the central nervous system will become more complex due to the emergence of secondary pathologies. Moreover, vascular dysfunction will also affect the cellular components of the neurovascular niche (such as pericytes). All of these factors should be included in the consideration of BBB modeling.

In Aβ transport study of AD, using the BBB model derived from iPSCs, it was found that the expression of LRP1 (responsible for Aβ excretion) was decreased in endothelial cells from AD patients, while the activity of RAGE (responsible for Aβ influx) was abnormal, leading to the deposition of Aβ in the vascular wall (amyloid angiopathy of the brain). Meanwwhile, in the microfluidic chip, by simulating the stimulation of Aβ oligomers, it was observed that pericytes contracted and underwent apoptosis before endothelial cells, resulting in the phenomenon of no reflow of capillaries (Lin et al., 2021). Besides, in PD study, it was confirmed that α-synuclein can cross the BBB via exosomes or in a free form, and can retrogradely enter the central nervous system from the intestine or peripheral nervous system. The efficiency of transendothelial migration and the resulting mitochondrial damage can be quantitatively detected in the 3D BBB model. To be noted, through the integration of microfluidic models, it was discovered that in the context of systemic inflammation induced by LPS, activated T cells are more likely to penetrate the dysfunctional BBB, thereby exacerbating the death of dopaminergic neurons (de Rus et al., 2023). Moreover, using the iPSC-BBB model carrying the C9orf72 mutation, it was found that the chemokines secreted by ECs (such as MCP-1) were abnormally increased, which disrupted the barrier integrity of the model and induced abnormal infiltration of peripheral monocytes, simulating the immune infiltration phenomenon observed in the spinal cord of ALS patients (Mohi-Ud-Din et al., 2022). Meanwhile, neuroinflammation is a core pathological feature of many neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, and traumatic brain injury. However, traditional brain organoids typically lack functional immune populations, especially microglia; other immune components, such as perivascular macrophages and peripheral immune cells, are also largely absent. Therefore, traditional organoids cannot fully replicate the neuroinflammation mediated by microglia, cytokine release, synaptic pruning, or the neuronal-glial-immune interactions. Organoids containing microglia generated through co-culture or directed differentiation can partially restore these interactions, and provide a promising platform for simulating neuroinflammatory phenotypes, disease-related microglial states, and immune regulatory therapies. Anyway, there are still challenges in terms of the maturation of microglia, regional characteristics, density, and batch-to-batch reproducibility. Integrating microglia and other immune components into vascularized and BBB/NVU models is crucial for enhancing the relevance of disease studies and the predictive validity of drug response research.

As already known, validation of human diseases is crucial for determining the relevance of organoid phenotypes. Ideally, the discoveries derived from organoids should be compared with patient-derived tissues, neuropathological findings, clinical imaging, cerebrospinal fluid biomarkers, and human molecular datasets. For instance, the transcriptomics, proteomics, and epigenetic profiles of organoids should be cross-referenced with human brain datasets, single-cell maps, and disease-related molecular features. Neuropathological features, such as protein aggregation, glial activation, and synaptic loss, should be compared with post-mortem human tissues. Clinical imaging and cerebrospinal fluid biomarkers can further provide in vivo relevance of the organoid-derived phenotypes (Mencattini et al., 2025). This multi-modal validation is necessary because the organoid phenotypes themselves may reflect incomplete maturation, culture-induced artifacts, or model-specific characteristics rather than the true disease mechanisms. Without validation against human disease, organoid findings should be considered hypothesis-generating rather than definitively disease-relevant. Standardized benchmarks, transparent reporting, and data sharing will therefore be critical for strengthening the translational value of brain organoid models.

Collectively, by exploring the known pathophysiological mechanisms of the blood-brain barrier (BBB), the relationship between the BBB and the extracellular matrix (ECM), and new models, we can conduct a more in-depth study of the pathophysiological processes involved in BBB modeling in the research of neurodegenerative diseases. On the other side, the main challenges currently faced are that the BBB of animal models significantly differs from that of humans in terms of transporters and immune molecule expression, resulting in a high failure rate in drug development and translation. The human-derived iPSC model is considered a key direction to solve this problem, but the functional maturity of its cells (such as the formation of true arteriovenous differentiation) still needs to be improved. Secondly, due to the dynamic complexity of the pathological development process, the BBB disruption in neurodegenerative diseases is dynamic and localized. Although the current models are becoming increasingly realistic in their static structures, how to simulate long-term, low-level chronic leakage (rather than acute damage) and regional heterogeneity (such as why the BBB in the hippocampus is more vulnerable) remain technical difficulties.

As already known, insufficient vascularization remains a major limitation of traditional brain organoids and many BBB/NVU models. In the absence of functional and perfusionary vascular networks, oxygen and nutrients cannot be effectively delivered to the core of the organoids, while metabolic waste accumulates. This typically leads to steep oxygen and nutrient gradients, hypoxic areas, necrotic cores, and changes in cellular metabolism, including a shift to glycolysis, increased cellular stress, and impaired neuronal and glial maturation. These effects can confound disease modeling and drug response studies, as hypoxia and metabolic stress can alter drug sensitivity, metabolic enzyme expression, transporter activity, and neuroinflammatory phenotypes. Meanwhile, several vascularization strategies have been developed, including co-culture of endothelial cells, vascularized organoids, microfluidic platforms, and in vivo transplantation, to promote host-derived vascularization. These methods can partially improve perfusion, reduce the formation of necrotic cores, and enhance cell survival and maturation. However, their effectiveness is still limited. Many vascularized organoids still lack complete perivascular coverage by pericytes and astrocytes, mature basement membranes, and consistent barrier properties. Perfusion is usually incomplete or heterogeneous, and reproducibility, throughput, and scalability remain challenging. Moreover, vascularization alone does not guarantee a fully functional BBB/NVU or reliable drug delivery to the brain parenchyma. Therefore, vascularization strategies should be regarded as partial and complementary solutions, and their effectiveness should be evaluated using standardized readouts of perfusion, oxygenation, metabolism, barrier integrity, and permeability. In the research of drug delivery based on organoids, blood-brain barrier permeability, tissue permeability, cellular uptake, toxicity and therapeutic efficacy represent different endpoints and should not be regarded as equivalent. BBB permeability requires the BBB/NVU model and is evaluated through TEER and tracer permeability; tissue penetration requires imaging or spatial analysis; cellular uptake is measured by flow cytometry or confocal imaging; toxicity requires survival rate and stress tests; therapeutic efficacy requires disease-related functional readouts. Independent cellular uptake does not indicate blood-brain barrier crossing or parenchymal delivery, and an increase in permeability does not guarantee therapeutic efficacy.

4. Evaluating drug transport based on BBB models

In order to identify the novel molecular targets for glioblastoma, the urgent requirement for developing therapeutic drugs that penetrate the blood-brain barrier. This highlights the importance of in vitro models of the blood-brain barrier as a catalyst for central nervous system drug discovery and screening (Bai et al., 2025). As mentioned above, the development of in vitro blood-brain barrier models (i.e. Transwell, spheroids/organoids, and microfluidics); However, although each model has its own advantages, design differences may lead to difficulties to standardizing and then evaluating blood-brain barrier features and application as screening models (Zhang et al., 2025; Shao et al., 2025). Therefore, compared to in vivo studies, permeability measurement is urgent for accessing the effectiveness of drugs transport in the blood-brain barrier.

4.1. High throughput screening of drugs

In the process of drug development, high-throughput screening (HTS) requires the detection of a range of active compounds (Xiao et al., 2022). Several blood-brain barrier models have been used for in vitro screening of drug targets (Appelt-Menzel et al., 2020). In order to evaluate the permeability of drugs, the Transwell co culture model is more popular as it allows for convenient and rapid screening of target compounds. For example, Han et al. designed a high-throughput transwell platform (HTS-BBB) specifically optimized for screening mRNA LNPs for screening the blood-brain barrier. Unlike most transwell assays that only evaluate endothelial monolayer transport, HTS-BBB simultaneously measures LNP transport and mRNA transfection in endothelial cells themselves. Then, they used HTS-BBB to screen 14 LNPs libraries made of ionizable lipids with different structures, and demonstrated their ability to predict in vivo performance by validating the main candidates for mRNA delivery to mouse brains after intravenous injection (Han et al., 2024; Gan et al., 2024). Although the limitations of Transwell, improvements have been made in vitro testing (Patient et al., 2019). Moreover, Qi et al. developed a new system, including a 3D printed scaffold and electrospun polylactic acid co glycolic acid (PLGA) nanofiber network, double-layer co-cultured human astrocytes and endothelial cells derived from human induced pluripotent stem cells (hiPSCs), in an electrospun PLGA network. In addition, co-culture of Hipsc derived astrocytes with endothelial cells promoted the expression of tight junction proteins and TEER values. The improved Transwell was also used to evaluate the anti-cancer drugs paclitaxel and bortezomib, which have limitation to enter the brain (Qi et al., 2018). However, high doses of paclitaxel and bortezomib lead to the decreased of TEER, thereby damaging the integrity of the barrier, which may have adverse side effects on patients. To address this issue, researchers have explored several strategies to improve drug delivery to the brain by temporarily compromising the integrity of the blood-brain barrier, such as enhanced convection or focused ultrasound delivery, which have been referred (Wang et al., 2022; Wasielewska and White, 2022).The study by Sherman et al. combined Corning ®HTS Transwell ®- The 96 tissue culture system and Corning 96 well spherical microplate, cultured MDCKII/MDR1on the inserts, and cultured glioma spheroids in the microplates. The resulting system can be customized for any number of cell types and screening applications, allowing for a more comprehensive study of drug transport across the blood-brain barrier and the resulting 3D glioma sphere toxicity. (Sherman and Rossi, 2019).

As mentioned previously, both spheroid and organoid models are helpful in summarizing cells interactions, and also the finds suggesting their ability in promoting high-throughput drugs screening (Jeong et al., 2023; Brandenberg et al., 2020); For instance, based on the BBB spheroid model, MPTP, a prodrug used to treat Parkinson's disease, significantly reduced ATP levels, while MPP+, due to its hydrophilicity, does not cross the blood-brain barrier and does not affect ATP production. (Sokolova et al., 2020a). Overall, spheroid models are becoming popular tools for HTS. However, these models are still not enough for detecting the drug function after crossing the BBB (Sokolova et al., 2020b). Although the structure and technology of microfluidic systems are complex, some teams have already manufactured microfluidic devices for high-throughput analysis (Bi et al., 2023). Early microfluidic models have tested the permeability of drugs (Annese and Hu, 2022), and Booth designed models have also evaluated the permeability of neuroactive drugs (Saleh et al., 2023). Due to its ability to conduct multiple experiments in parallel, this microfluidic platform can be used for HTS of novel brain cancer treatment methods. Doxorubicin is a widely used anti-cancer drug, known to have limited channels through the blood-brain barrier and reduced TEER values, indicating barrier disruption (Otter et al., 2021). Although the integrity of the blood-brain barrier is compromised, the permeability of doxorubicin remains unchanged and is more related to the stable expression of efflux transporters. The pump free and streamlined design of this model allows for robust sampling and drug management (Ito et al., 2021), making it convenient for high-throughput applications. The transport of doxorubicin was evaluated using the Pgp inhibitor verapamil, and the increase in doxorubicin permeability was studied. In addition, opening the barrier and inducing hypoxia can increase the penetration of cetuximab (Zhuo et al., 2024).

In summary, microfluidic devices are an effective model for drug screening and drug transport evaluation. In brain cancer cases, the blood-brain barrier and tumor microenvironment hinder clinical drug approval. In vitro blood-brain barrier models have been applied for drug screening, such as selecting kinase inhibitors in clinical trials of glioblastoma because they can cross the blood-brain barrier (Pinto-Fraga et al., 2024; Pinto-Fraga et al., 2025). Although animal studies remain the gold standard for validating new drugs or brain permeability inhibitors, it is necessary to standardize in vitro blood-brain barrier models to make them comparable to in vivo models.

4.2. Nanoparticle-based drug delivery

Usually, the blood-brain barrier hinders delivery, thereby affecting the efficacy of traditional drug formulations in clinical settings (Roghani et al., 2024). Due to the passive administration of these drugs through systemic administration, the incidence of systemic toxicity is high, which may lead to adverse side effects (Han and Jiang, 2021). In order to overcome the limitations of free drug molecules, nanotechnology has been used to develop cutting-edge drug delivery platforms that can encapsulate drugs or genetic material and deliver these therapeutic agents to specific targets in a controlled manner (Garbayo et al., 2020). In addition, many drug delivery platforms based on nanotechnology have been designed and applied in cancer (Hannon et al., 2023), among which nanoparticles have been widely used in clinical treatment of recurrent glioblastoma (Schwake et al., 2022). In the process of treating brain cancer, firstly, nanoparticles have the potential to enhance their permeability to the brain and more effectively deliver drugs to specific areas. Ideally, when their size is <40 nm (Mineiro et al., 2023). In addition, the enhancement of vascular leakage in brain tumors may increase the possibility of passive accumulation of nanoparticles or enhance permeability and retention (EPR) effects (Caro et al., 2021). Similarly, the EPR effect not only affects the penetration of nanoparticles into brain tumors, as most nanoparticles have been shown to utilize cross cellular transport, particularly receptor-mediated endocytosis (Mao et al., 2024). This can be achieved by changing the surface function of nanoparticles, allowing them to cross the blood-brain barrier and penetrate brain tumors. In this case, designing nanoparticles requires consideration of several factors.

4.2.1. Factors affecting the transport of nanoparticles through the BBB

The nanoparticles can be modified according to some parameters, including composition, size, charge, shape, surface coating, and forms of functionalization to enhance the penetration (Fig. 8). For instance, drug loaded nanoparticles can stimulate passive uptake of brain ECs by increasing local drug concentration (Kopatz et al., 2023). In active transport, the surface features of nanoparticles can enhance their interaction or ligand binding with brain specific receptors through receptor-mediated endocytosis (Tylawsky et al., 2023). The transferrin receptor (TfR) is commonly used to increase the accumulation and transport of nanoparticles to brain, highly expressing in the blood-brain barrier. Some nanoparticles functionalized with transferrin, lactoferrin, TfR-specific antibodies or peptides to enhance their access to brain (Thomsen et al., 2022; Xiao et al., 2021). Li et al. have modified the surface of nanoparticles with lactoferrin (Lf) to improve blood-brain barrier crossing and target glioma cells through receptor-mediated pathways (El-Fakharany, 2020).

The success of nanoparticles passing through the blood-brain barrier also depends on their size (Jain and Bhise, 2025). The study has reported that particles with a diameter between 20 and 50 nm have higher permeability on the blood-brain barrier, while larger particles (100 nm or larger) typically require surface modification to stimulate the active transport (Borràs et al., 2022). Shen et al. have also suggested that the phrase of glioblastoma affects the nanoparticles with different sizes that can cross the blood-brain barrier (Shen et al., 2020). With the development of diseases, the degree of vascular leakage increasing, Therefore, in the late stage of glioblastoma, the larger nanoparticles can also cross the blood-brain barrier (Le et al., 2021). In addition, the main chemical components of nanoparticles, whether polymer based, lipid based, or metal based, can also decide their fate in the brain endothelium (Abdelgader et al., 2025). Lipid nanoparticles have natural biocompatibility and biodegradability (Khare et al., 2023). Small solid lipid nanoparticles (approximately 40-200 nm) tend to penetrate the brain endothelium (Scioli Montoto et al., 2020). However, regardless of size, larger liposomes (i.e. 200 and 500 nm) exhibit higher blood-brain barrier permeability (Mourtas et al., 2020). The presence of hydrophilic coatings of nanoparticles increases the opportunity for passive transport through the blood-brain barrier, as it tends to prolong circulation time. In addition, coating with PEG and polypropylene glycol may inhibit the activity of the efflux-pump (Tehrani et al., 2022).

As mentioned above, the permeability of nanoparticles across the blood-brain barrier is influenced by a variety of physical and chemical properties (such as size, shape, surface charge, stiffness, ligand density and protein corona) as well as biological factors (such as endothelial phenotype, receptor expression, culture conditions and flow rate). Moreover, cellular uptake, transcellular transport and brain parenchymal delivery represent different processes. Cellular uptake reflects the internalization of endothelial cells; transcytosis refers to the transport across the endothelial monolayer; while actual brain parenchymal delivery requires nanoparticles to pass through the blood vessel wall and accumulate in the brain parenchyma. Therefore, evidence of endothelial uptake alone should not be equated with blood-brain barrier crossing or brain delivery; conclusions regarding parenchymal delivery require direct in vivo or in vitro confirmation. Collectively, the permeability coefficient of the blood-brain barrier is largely affected by particle size, surface composition, charge, shape, as well as stiffness. In addition, the ligand in surface also enhances the permeability of the blood-brain barrier. Additionally, evaluating the in vitro model of drug permeability through the blood-brain barrier based on nanoparticles is crucial for prioritizing nanoparticle formulations in pre-clinical studies. To be noted, Patient-derived and iPSC-derived organoids offer promising opportunities for personalized medicine, including patient-specific disease modeling and drug response testing. However, their potential must be balanced against donor variability, reprogramming-related effects, incomplete maturation, genetic instability, and differentiation variability. These factors will affect cell composition, functional characteristics, reproducibility, and drug response. Therefore, standardized protocols, gene-level control, multi-donor validation, and genomic stability monitoring are of utmost importance.

4.2.2. The nanoparticles in BBB models screening

Since the simplicity and HTS capability of Transwell, it is used for accessing the delivery by nanoparticles (Gimondi et al., 2023). Indeed, they also have limitations in nanoparticles as some formulations may self-aggregate or membrane adhering (Li et al., 2021). Hanada et al. have compared the permeability of three sizes of silica nanoparticles by Transwell and the results revealed that the smallest size of silica nanoparticles had a higher permeability (Hudecz et al., 2020). Researchers have also measured the effects of various surface charges (anions, cations, and neutrality) on the functional groups of quantum dots, where the results shown that amino functionalized (NH2-) nanoparticles were more effective in crossing the blood-brain barrier (Mauri et al., 2020). Further, they indicated that serum-contained media may reduce permeability values and lead to nanoparticle aggregation (Barbero et al., 2022). Meanwhile, others have evaluated polymer based nanoparticles, loaded with doxorubicin and Docetaxel loaded PEG polylactic acid (PEG-PLA) glutathione coating for the treatment of brain tumors (Neumaier et al., 2021). At present, researchers have investigated the permeability and cytotoxicity of two triblock copolymer nanoparticles, which is attributed to the accelerated release of atorvastatin (ATV) from the micelles or the disruption of the ATV loaded micelles (Szewczyk-Łagodzińska et al., 2023). Norouzi et al. have investigated the permeability of magnetic iron oxide nanoparticles stably loaded with doxorubicin using trimethoxysilylpropyl ethylenediamine triacetic acid (DOX EDTIONPs) in glioblastoma chemotherapy (Norouzi et al., 2020). Bruns et al. have seeded GBM spheroids at the stiffness interface and examined for viability, size, invasion, laminin expression, hypoxia, proliferation, and response to the chemotherapeutic temozolomide (TMZ) (Bruns et al., 2023). Leite et al. used human iPSC-spheroids to compare the effects of gold nanoparticles functionalized with sodium citrate (Au-SC) or polyethylene glycol (Au-PEG) and PLA-NP (Leite et al., 2019). Additionally, the small size of nanoparticles (2 nm) makes them unsuitable as transport carriers for biomolecules such as proteins or antibodies, and puts them at risk of premature separation and elimination by the kidneys. Therefore, the blood-brain barrier spherical model has potential value in screening nanoparticles, provided that the design and delivery of nanoparticles also consider other cellular barriers (Hadrup et al., 2024; Singh et al., 2021).

Due to its advantages, microfluidic models have the potential to test drugs and drug loaded nanoparticles. Falanga et al. have used a microfluidic blood-brain barrier model to test the transport of gH625 conjugated nanoparticles under flow conditions (Zhong et al., 2023). The presence of the EC layer hinders the transport of fluorescent nanoparticles modified with reference amines. In contrast, under flow conditions, gH625 conjugated nanoparticles effectively transfer on the EC layer. As mentioned above, the surface modified nanoparticles can enhance receptor-mediated endocytosis. As known, angiopep-2 is a peptide containing 19 residues that can cross the blood-brain barrier through the low-density lipoprotein receptor associated protein-1 (LRP-1) receptor. It is usually coupled with nanoparticles to promote the binding and internalization of ECs (Cao et al., 2023). The researchers have generated high-density lipoprotein mimicking nanoparticles that promote drug delivery by lipoprotein receptor-mediated endocytosis.The high-density simulated lipoprotein nanoparticles modified with apolipoprotein A1 (eHNP-A1) were evaluated using a microfluidic chip (Ahn et al., 2020). Taken together, the microfluidic methods emphasized in these studies are capable of 3D mapping of the blood-brain barrier and the distribution of nanoparticles within the blood-brain barrier.

5. Future perspectives

Considering the increasingly advanced brain barrier models, improving and expanding these models in 3D space to overcome the challenges of brain cancer treatment is a huge opportunity. As is well known, combining various aspects of tumor cells and microenvironment, such as immune cells and ECM components, can establish more biologically relevant models for the blood-brain barrier/blood-brain barrier affected by tumors, which can then be used to evaluate immune targeted therapy (Qiu et al., 2021). Bioengineering microfluidic models use collagen hydrogels to better simulate the characteristics of the blood-brain barrier. However, more physiological matrices, such as hydrogels made of hyaluronic acid or proteoglycan, may improve these models (Gu et al., 2022). Some researchers have developed a system that uses bioinks that simulate the blood-brain barrier to establish the blood-brain barrier vascular system in situ (Daughters et al., 2024). These bio 3D printing technologies use bioinks or polymer networks and hydrophilic molecules composed of various materials such as collagen, hyaluronic acid, alginate, etc., which have great potential to print multi-layer biocompatible scaffolds of different cell types for rapid drug screening (Xiang et al., 2024; Piras and Smith, 2020). As is well known, other components of the blood-brain barrier, particularly astrocytes and pericytes, are involved in enhancing the integrity of the blood-brain barrier. The development of 3D brain organoids, including various cell types, helps to address this limitation (Hopf et al., 2024). However, they still lack blood vessels and ECM, and the addition of VEGF or ECM may be necessary to promote endothelial cell germination and induce cell matrix interactions, which are crucial for the function of ECs (Wang et al., 2025; Cameron et al., 2021).

The future progress of incorporating blood vessels, ECM, and brain TME into organoids will provide an interesting system/platform. In addition, combining the blood-brain barrier spheres or organoids of tumor cells as a tool for drug permeability screening also has great prospects. In terms of blood-brain barrier/blood-brain barrier drug delivery, several brain drug delivery techniques have been adopted, including convection enhanced drug delivery, focused ultrasound, nanomedicine, etc. In an in vitro blood-brain barrier model, the technique of instantaneous opening of the blood-brain barrier can be used for drug screening. Nanoparticle technology is an extraordinary drug delivery tool, however, the formulation of nanoparticles is constantly being improved to enhance drug delivery capabilities. Alternative strategies that bypass the blood-brain barrier, particularly nose to brain delivery, have also attracted increasing attention. Intranasal administration can deliver therapeutic drugs to the central nervous system through the olfactory and trigeminal nerve pathways, thereby circumventing the BBB. However, the efficiency, reproducibility, and clinical translatability of nose to brain delivery are affected by formulation characteristics, delivery devices, mucociliary clearance rates, and species-specific anatomical differences. Therefore, these methods may complement rather than replace delivery strategies targeting the BBB and based on NVU (Raghav et al., 2023). It is worth noting that the in vitro blood-brain barrier model can provide a method for tracking nanoparticles and their payloads, fundamentally understanding the penetration and accumulation of nanoparticles in the brain. Recently, cancer immunotherapy targeting immune checkpoint blockade has received increasing attention as a powerful strategy for treating solid tumors (Meng et al., 2021). As with most central nervous system treatments, one of the challenges of immunotherapy is overcoming the BBB.

Totally, BBB modeling has evolved from simple barrier function assessment to the simulation of the overall function of the “neurovascular unit”. The key value in the future lies in how to distinguish whether BBB disruption is the “cause” or “result” of the disease, how to use the model to search for liquid biopsy markers that reflect early BBB damage, and how to verify on such models the strategy of achieving efficient delivery of large molecule drugs (such as antisense oligonucleotides, antibodies) into the brain by targeting BBB transporters. And also we have proposed a step-by-step framework: 2D cell analysis for target identification and mechanism research; brain organoids and BBB/NVU models for human-related 3D disease modeling and drug delivery assessment; vascularized organoids, multi-cell aggregates, and organ systems on chips to enhance the complexity of the NVU and quantitative barrier reading; animal studies on systemic pharmacokinetics, metabolism, immune response, blood flow, and systemic toxicity; and finally, clinical evaluation of human safety, efficacy, and patient outcomes. In this framework, organoids supplement rather than replace the existing models, and their findings need to be verified based on both animal and human data.

6. Conclusion

Although 3D based cell technology has fundamentally changed preclinical research, its applicability and characteristics to the blood-brain barrier remain a fundamental area for further learning. As alternatives to animal models, these models are receiving increasing attention. Improved traditional Transwell and advanced engineering techniques have been applied to microfluidic models; However, these methods are often limited by their inability to summarize the complex three-dimensional and heterogeneous brain microenvironment. On the other hand, sphere or organoid models have attracted great interest due to their focus on cellular interactions. Especially for organoids, they have attracted more attention due to their ability to simulate complex 3D tissue structures and preserve their ECM components. To be noted, brain organoids often exhibit transcriptional and functional characteristics similar to those of a fetus. Incomplete maturation of neurons may lead to immature synaptic networks, changes in electrophysiological properties, reduced diversity of neuronal subtypes, and limited ability to simulate late-onset neurodegenerative changes. Incomplete maturation of glial cells, including astrocytes, oligodendrocytes, and microglia may further impair myelin formation, nutrient support, synaptic pruning, and neuroinflammatory responses. Since many disease phenotypes and drug responses are regulated by development, these limitations may cause organ-based disease modeling to favor early developmental stages and reduce the predictive validity of drug response studies. In particular, immature expression of receptors, ion channels, metabolic enzymes, and efflux transporters may alter drug sensitivity, metabolism, and toxicity. Therefore, the findings derived from organoids should be interpreted with caution. Strategies for maturation and aging need to be improved, and the results should be verified on human tissues. As these challenges are more reliably and physiologically addressed and characterized in the future, these highly advanced engineering models will provide a platform for accelerating clinical trials of new therapies for brain cancer and other central nervous system diseases.

CRediT authorship contribution statement

Qiong Xiang: Writing – review & editing, Writing – original draft, Visualization, Validation, Funding acquisition, Formal analysis, Data curation, Conceptualization. Ming-Xin Zheng: Writing – review & editing, Writing – original draft, Software, Methodology, Formal analysis, Data curation. Jing-Ru Yuan: Writing – review & editing, Writing – original draft, Validation, Investigation, Formal analysis, Data curation. Song-Rong Lin: Writing – review & editing, Writing – original draft, Validation, Investigation, Formal analysis. Xiao-Da Li: Writing – review & editing, Writing – original draft, Validation, Funding acquisition. Xian-Hui Li: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Funding acquisition, Data curation, Conceptualization.

Funding statement

The work was supported by the Natural Science Foundation of Hunan Province (No.2025JJ70598); The Key Project of Hunan Provincial Department of Education (No.25A0402); The U40 project for QX;The College Students Innovative Training Project (No.S202610531110, No.S202610531108) and The Hunan Provincial Research Project on Teaching Reform in Degree and Graduate Education (No. 2025JGYB309).

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

Data availability is not applicable to this review article as no new data were created or analyzed in this study.

References

  1. Abdelgader A., Govender M., Kumar P., Choonara Y.E. A novel intrauterine device for the extended tissue-specific release of estradiol and norethindrone to treat the genitourinary syndrome of menopause. Polymers (Basel) 2025;17(5):665. doi: 10.3390/polym17050665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Abu-Nab A.K., Morad A.M., Selima E.S., Kanagawa T., Abu-Bakr A.F. A review of microcavitation bubbles dynamics in biological systems and their mechanical applications. Ultrason. Sonochem. 2025;121 doi: 10.1016/j.ultsonch.2025.107521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ahishali B., Kaya M. Evaluation of blood-brain barrier integrity using vascular permeability markers: evans blue, sodium fluorescein, albumin-alexa fluor conjugates, and horseradish peroxidase. Methods Mol. Biol. 2021;2367:87–103. doi: 10.1007/7651_2020_316. [DOI] [PubMed] [Google Scholar]
  4. Ahn S.I., Sei Y.J., Park H.J., Kim J., Ryu Y., Choi J.J., Sung H.J., MacDonald T.J., Levey A.I., Kim Y. Microengineered human blood-brain barrier platform for understanding nanoparticle transport mechanisms. Nat. Commun. 2020;11(1):175. doi: 10.1038/s41467-019-13896-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Alnaqbi N., Mohammad M.G., Hamoudi R., Mabondzo A., Harati R. Molecular heterogeneity of the brain endothelium. Curr. Issues Mol. Biol. 2023;45(4):3462–3478. doi: 10.3390/cimb45040227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Alves A.D.H., Nucci M.P., Ennes do Valle N.M., Missina J.M., Mamani J.B., GNA Rego, OFM Dias, Garrigós M.M., de Oliveira F.A., Gamarra L.F. Current overview of induced pluripotent stem cell-based blood-brain barrier-on-a-chip. World J. Stem Cells. 2023;15(6):632–653. doi: 10.4252/wjsc.v15.i6.632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Andjelkovic A.V., Stamatovic S.M., Phillips C.M., Martinez-Revollar G., Keep R.F. Modeling blood-brain barrier pathology in cerebrovascular disease in vitro: current and future paradigms. Fluids Barriers CNS. 2020;17(1):44. doi: 10.1186/s12987-020-00202-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Andrade Mier M.S., Bakirci E., Stahlhut P., Blum R., Dalton P.D., Villmann C. Primary glial cell and glioblastoma morphology in cocultures depends on scaffold design and hydrogel composition. Adv. Biol. (Weinh) 2023;7(10) doi: 10.1002/adbi.202300029. [DOI] [PubMed] [Google Scholar]
  9. Angom R.S., Nakka N.M.R., Bhattacharya S. Advances in glioblastoma therapy: an update on current approaches. Brain Sci. 2023;13(11):1536. doi: 10.3390/brainsci13111536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Angom R.S., Nakka N.M.R., Bhattacharya S. Advances in glioblastoma therapy: an update on current approaches. Brain Sci. 2023;13(11):1536. doi: 10.3390/brainsci13111536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Annese V.F., Hu C. Integrating microfluidics and electronics in point-of-care diagnostics: current and future challenges. Micromachines (Basel) 2022;13(11):1923. doi: 10.3390/mi13111923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Anwar M.M., Özkan E., Gürsoy-Özdemir Y. The role of extracellular matrix alterations in mediating astrocyte damage and pericyte dysfunction in Alzheimer's disease: a comprehensive review. Eur. J. Neurosci. 2022;56(9):5453–5475. doi: 10.1111/ejn.15372. [DOI] [PubMed] [Google Scholar]
  13. Appelt-Menzel A., Oerter S., Mathew S., Haferkamp U., Hartmann C., Jung M., Neuhaus W., Pless O. Human iPSC-derived blood-brain barrier models: valuable tools for preclinical drug discovery and development? Curr. Protoc. Stem Cell Biol. 2020;55(1) doi: 10.1002/cpsc.122. [DOI] [PubMed] [Google Scholar]
  14. Arvanitis C.D., Ferraro G.B., Jain R.K. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat. Rev. Cancer. 2020;20(1):26–41. doi: 10.1038/s41568-019-0205-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Aye K.T.N., Ferreira J.N., Chaweewannakorn C., Souza G.R. Advances in the application of iron oxide nanoparticles (IONs and SPIONs) in three-dimensional cell culture systems. SLAS Technol. 2024;29(3) doi: 10.1016/j.slast.2024.100132. [DOI] [PubMed] [Google Scholar]
  16. Bai Q., Tang H., Chen Y., Pan Z., Lin W., Wang L., Hu Y., Xu B., Yang M., Zhao G., Sun W., He Y., Chen C. Modular strategy with autologous bioreactor: a potential way for organ engineering. Int. J. Extreme Manuf. 2025;7(2) [Google Scholar]
  17. Balda M.S., Matter K. Tight junctions. Curr. Biol. 2023;33(21):R1135–R1140. doi: 10.1016/j.cub.2023.09.027. [DOI] [PubMed] [Google Scholar]
  18. Barbero F., Michelini S., Moriones O.H., Patarroyo J., Rosell J., F Gusta M., Vitali M., Martín L., Canals F., Duschl A., Horejs-Hoeck J., Mondragón L., Bastús N.G., Puntes V. Role of common cell culture media supplements on citrate-stabilized gold nanoparticle protein corona formation, aggregation state, and the consequent impact on cellular uptake. Bioconjug. Chem. 2022;33(8):1505–1514. doi: 10.1021/acs.bioconjchem.2c00232. [DOI] [PubMed] [Google Scholar]
  19. Basheer A.S., Abas F., Othman I., Naidu R. Role of inflammatory mediators, macrophages, and neutrophils in glioma maintenance and progression: mechanistic understanding and potential therapeutic applications. Cancers (Basel) 2021;13(16):4226. doi: 10.3390/cancers13164226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Bi W., Cai S., Lei T., Wang L. Implementation of blood-brain barrier on microfluidic chip: recent advance and future prospects. Ageing Res. Rev. 2023;87 doi: 10.1016/j.arr.2023.101921. [DOI] [PubMed] [Google Scholar]
  21. Bickel M.A., Csik B., Gulej R., Ungvari A., Nyul-Toth A., Conley S.M. Cell non-autonomous regulation of cerebrovascular aging processes by the somatotropic axis. Front. Endocrinol. (Lausanne) 2023;14:1087053. doi: 10.3389/fendo.2023.1087053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Blanchard R., Adjei I. Engineering the glioblastoma microenvironment with bioactive nanoparticles for effective immunotherapy. RSC Adv. 2023;13(45):31411–31425. doi: 10.1039/d3ra01153d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Boric M.P., Durán W.N., Figueroa X.F. Editorial: cell communication in vascular biology. Front. Physiol. 2021;12 doi: 10.3389/fphys.2021.656959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Borràs C., Mercer A., Sirisi S., Alcolea D., Escolà-Gil J.C., Blanco-Vaca F., Tondo M. HDL-like-mediated cell cholesterol trafficking in the central nervous system and Alzheimer's disease pathogenesis. Int. J. Mol. Sci. 2022;23(16):9356. doi: 10.3390/ijms23169356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Brandenberg N., Hoehnel S., Kuttler F., Homicsko K., Ceroni C., Ringel T., Gjorevski N., Schwank G., Coukos G., Turcatti G., Lutolf M.P. High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays. Nat Biomed. Eng. 2020;4(9):863–874. doi: 10.1038/s41551-020-0565-2. [DOI] [PubMed] [Google Scholar]
  26. Bruns J., Egan T., Mercier P., Zustiak S.P. Glioblastoma spheroid growth and chemotherapeutic responses in single and dual-stiffness hydrogels. Acta Biomater. 2023;163:400–414. doi: 10.1016/j.actbio.2022.05.048. [DOI] [PubMed] [Google Scholar]
  27. Bull D., Schweitzer C., Bichsel C., Britschgi M., Gutbier S. Generation of an hiPSC-derived co-culture system to assess the effects of neuroinflammation on blood-brain barrier integrity. Cells. 2022;11(3):419. doi: 10.3390/cells11030419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Cameron T., Bennet T., Rowe E.M., Anwer M., Wellington C.L., Cheung K.C. Review of design considerations for brain-on-a-chip models. Micromachines (Basel) 2021;12(4):441. doi: 10.3390/mi12040441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Campisi M., Lim S.H., Chiono V., Kamm R.D. 3D self-organized human blood-brain barrier in a microfluidic chip. Methods Mol. Biol. 2021;2258:205–219. doi: 10.1007/978-1-0716-1174-6_14. [DOI] [PubMed] [Google Scholar]
  30. Candelario-Jalil E., Dijkhuizen R.M., Magnus T. Neuroinflammation, stroke, blood-brain barrier dysfunction, and imaging modalities. Stroke. 2022;53(5):1473–1486. doi: 10.1161/STROKEAHA.122.036946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Cantidio F.S., Gil G.O.B., Queiroz I.N., Regalin M. Glioblastoma - treatment and obstacles. Rep. Pract. Oncol. Radiother. 2022;27(4):744–753. doi: 10.5603/RPOR.a2022.0076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Cao Z., Liu X., Zhang W., Zhang K., Pan L., Zhu M., Qin H., Zou C., Wang W., Zhang C., He Y., Lin W., Zhang Y., Han D., Li M., Gu J. Biomimetic macrophage membrane-camouflaged nanoparticles induce ferroptosis by promoting mitochondrial damage in glioblastoma. ACS Nano. 2023;17(23):23746–23760. doi: 10.1021/acsnano.3c07555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Caro C., Avasthi A., Paez-Muñoz J.M., Pernia Leal M., García-Martín M.L. Passive targeting of high-grade gliomas via the EPR effect: a closed path for metallic nanoparticles? Biomater. Sci. 2021;9(23):7984–7995. doi: 10.1039/d1bm01398j. [DOI] [PubMed] [Google Scholar]
  34. Castiglione H., Vigneron P.A., Baquerre C., Yates F., Rontard J., Honegger T. Human brain organoids-on-chip: advances, challenges, and perspectives for preclinical applications. Pharmaceutics. 2022;14(11):2301. doi: 10.3390/pharmaceutics14112301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Castiglione H., Vigneron P.A., Baquerre C., Yates F., Rontard J., Honegger T. Human brain organoids-on-chip: advances, challenges, and perspectives for preclinical applications. Pharmaceutics. 2022;14(11):2301. doi: 10.3390/pharmaceutics14112301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Chaulagain B., Gothwal A., Lamptey R.N.L., Trivedi R., Mahanta A.K., Layek B., Singh J. Experimental models of in vitro blood-brain barrier for CNS drug delivery: an evolutionary perspective. Int. J. Mol. Sci. 2023;24(3):2710. doi: 10.3390/ijms24032710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Chen J., Lin Z., Barrett L., Dai L., Qin Z. Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG) Bioorg. Chem. 2020;99 doi: 10.1016/j.bioorg.2020.103847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Chen M., Niclis J.C., Denham M. Protocol for generating reproducible miniaturized controlled midbrain organoids. STAR Protoc. 2023;4(3) doi: 10.1016/j.xpro.2023.102451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Chen Y.X., Wei C.X., Lyu Y.Q., Chen H.Z., Jiang G., Gao X.L. Biomimetic drug-delivery systems for the management of brain diseases. Biomater. Sci. 2020;8(4):1073–1088. doi: 10.1039/c9bm01395d. [DOI] [PubMed] [Google Scholar]
  40. Cherubini M., Haase K. A bioengineered model for studying vascular-pericyte interactions of the placenta. Methods Mol. Biol. 2023;2608:409–423. doi: 10.1007/978-1-0716-2887-4_23. [DOI] [PubMed] [Google Scholar]
  41. Choi J.H., Choi H.K., Lee K.B. In situ detection of neuroinflammation using multi-cellular 3D neurovascular unit-on-a-chip. Adv. Funct. Mater. 2023;33(46):2304382. doi: 10.1002/adfm.202304382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Choi J.W., Kim K., Mukhambetiyar K., Lee N.K., Sabaté Del Río J., Joo J., Park C.G., Kwon T., Park T.E. Organ-on-a-chip approach for accelerating blood-brain barrier nanoshuttle discovery. ACS Nano. 2024;18(22):14388–14402. doi: 10.1021/acsnano.4c00994. [DOI] [PubMed] [Google Scholar]
  43. Choi Y., Jang H.S., Shim J., Yeo E., Kim M.H., Noh H., Oh S., Park J.H., Lee D., Lee J.H. 3D keloid spheroid model: development and application for personalized drug response prediction. Commun. Biol. 2024;7(1):1470. doi: 10.1038/s42003-024-07194-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Crouch E.E., Joseph T., Marsan E., Huang E.J. Disentangling brain vasculature in neurogenesis and neurodegeneration using single-cell transcriptomics. Trends Neurosci. 2023;46(7):551–565. doi: 10.1016/j.tins.2023.04.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Cui Y., Lee P., Reardon J.J., Wang A., Lynch S., Otero J.J., Sizemore G., Winter J.O. Evaluating glioblastoma tumour sphere growth and migration in interaction with astrocytes using 3D collagen-hyaluronic acid hydrogels. J. Mater. Chem. B. 2023;11(24):5442–5459. doi: 10.1039/d3tb00066d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Dabbagh F., Schroten H., Schwerk C. In vitro models of the blood-cerebrospinal fluid barrier and their applications in the development and research of (neuro)pharmaceuticals. Pharmaceutics. 2022;14(8):1729. doi: 10.3390/pharmaceutics14081729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Daughters R.S., Julian L., Knock E., Willerth S.M. Editorial: next generation in vitro models of the human blood - brain/cerebrospinal fluid barrier. Front. Mol. Neurosci. 2024;17:1371733. doi: 10.3389/fnmol.2024.1371733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. de Rus Jacquet A., Alpaugh M., Denis H.L., Tancredi J.L., Boutin M., Decaestecker J., Beauparlant C., Herrmann L., Saint-Pierre M., Parent M., Droit A., Breton S., Cicchetti F. The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson's disease. Nat. Commun. 2023;14(1):3651. doi: 10.1038/s41467-023-39038-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Delannoy E., Tellier G., Cholet J., Leroy A.M., Treizebré A., Soncin F. Multi-layered human blood vessels-on-chip design using double viscous finger patterning. Biomedicines. 2022;10(4):797. doi: 10.3390/biomedicines10040797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Deligne C., Hachani J., Duban-Deweer S., Meignan S., Leblond P., Carcaboso A.M., Sano Y., Shimizu F., Kanda T., Gosselet F., Dehouck M.P., Mysiorek C. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance. Fluids Barriers CNS. 2020;17(1):37. doi: 10.1186/s12987-020-00198-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Du X., Chen C., Yang L., Cui Y., Tan B. Bibliometric and visualized analysis of the application of nanotechnology in glioma. Front. Pharmacol. 2022;13 doi: 10.3389/fphar.2022.995512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. El-Fakharany E.M. Nanoformulation of lactoferrin potentiates its activity and enhances novel biotechnological applications. Int. J. Biol. Macromol. 2020;165(Pt A):970–984. doi: 10.1016/j.ijbiomac.2020.09.235. [DOI] [PubMed] [Google Scholar]
  53. Erices J.I., Bizama C., Niechi I., Uribe D., Rosales A., Fabres K., Navarro-Martínez G., Torres Á., San Martín R., Roa J.C., Quezada-Monrás C. Glioblastoma microenvironment and invasiveness: new insights and therapeutic targets. Int. J. Mol. Sci. 2023;24(8):7047. doi: 10.3390/ijms24087047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Farshbaf M., Mojarad-Jabali S., Hemmati S., Khosroushahi A.Y., Motasadizadeh H., Zarebkohan A., Valizadeh H. Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers. J. Control. Release. 2022;345:371–384. doi: 10.1016/j.jconrel.2022.03.019. [DOI] [PubMed] [Google Scholar]
  55. Fertan E., Böken D., Murray A., Danial J.S.H., Lam J.Y.L., Wu Y., Goh P.A., Alić I., Cheetham M.R., Lobanova E., Zhang Y.P., Nižetić D., Klenerman D. Cerebral organoids with chromosome 21 trisomy secrete Alzheimer's disease-related soluble aggregates detectable by single-molecule-fluorescence and super-resolution microscopy. Mol. Psychiatry. 2024;29(2):369–386. doi: 10.1038/s41380-023-02333-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Gan Y., Yu Y., Xu H., Piao H. Tliposomal nanomaterials: a rising star in glioma treatment. Int. J. Nanomedicine. 2024;19:6757–6776. doi: 10.2147/IJN.S470478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Garbayo E., Pascual-Gil S., Rodríguez-Nogales C., Saludas L., Estella-Hermoso de Mendoza A., Blanco-Prieto M.J. Nanomedicine and drug delivery systems in cancer and regenerative medicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2020;12(5) doi: 10.1002/wnan.1637. [DOI] [PubMed] [Google Scholar]
  58. Garcia-Gallardo A., Campbell M. Understanding the blood-brain barrier: from physiology to pathology. Adv. Exp. Med. Biol. 2025;1477:1–33. doi: 10.1007/978-3-031-89525-8_1. [DOI] [PubMed] [Google Scholar]
  59. Gelat B., Rathaur P., Malaviya P., Patel B., Trivedi K., Johar K., Gelat R. The intervention of epithelial-mesenchymal transition in homeostasis of human retinal pigment epithelial cells: a review. J. Histotechnol. 2022;45(4):148–160. doi: 10.1080/01478885.2022.2137665. [DOI] [PubMed] [Google Scholar]
  60. Gericke B., Borsdorf S., Wienböker I., Noack A., Noack S., Löscher W. Similarities and differences in the localization, trafficking, and function of P-glycoprotein in MDR1-EGFP-transduced rat versus human brain capillary endothelial cell lines. 2021;18(1):36. doi: 10.1186/s12987-021-00266-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Gimondi S., Ferreira H., Reis R.L., Neves N.M. Microfluidic devices: a tool for nanoparticle synthesis and performance evaluation. ACS Nano. 2023;17(15):14205–14228. doi: 10.1021/acsnano.3c01117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Girard S.D., Julien-Gau I., Molino Y., Combes B.F., Greetham L., Khrestchatisky M., Nivet E. High and low permeability of human pluripotent stem cell-derived blood-brain barrier models depend on epithelial or endothelial features. FASEB J. 2023;37(2) doi: 10.1096/fj.202201422R. [DOI] [PubMed] [Google Scholar]
  63. Gray K.M., Jung J.W., Inglut C.T., Huang H.C., Stroka K.M. Quantitatively relating brain endothelial cell-cell junction phenotype to global and local barrier properties under varied culture conditions via the Junction Analyzer Program. Fluids Barriers CNS. 2020;17(1):16. doi: 10.1186/s12987-020-0177-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Gu J., Gao B., Zafar H., Chu B., Feng X., Ni Y., Xu L., Bao R. Thermo-sensitive hydrogel combined with SHH expressed RMSCs for rat spinal cord regeneration. Front. Bioeng. Biotechnol. 2022;10:1001396. doi: 10.3389/fbioe.2022.1001396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Hadrup N., Vogel U., Jacobsen N.R. Biokinetics of carbon black, multi-walled carbon nanotubes, cerium oxide, silica, and titanium dioxide nanoparticles after inhalation: a review. Nanotoxicology. 2024;18(8):678–706. doi: 10.1080/17435390.2024.2431242. [DOI] [PubMed] [Google Scholar]
  66. Hajal C., Offeddu G.S., Shin Y., Zhang S., Morozova O., Hickman D., Knutson C.G., Kamm R.D. Engineered human blood-brain barrier microfluidic model for vascular permeability analyses. Nat. Protoc. 2022;17(1):95–128. doi: 10.1038/s41596-021-00635-w. [DOI] [PubMed] [Google Scholar]
  67. Hajal C., Offeddu G.S., Shin Y., Zhang S., Morozova O., Hickman D., Knutson C.G., Kamm R.D. Engineered human blood-brain barrier microfluidic model for vascular permeability analyses. Nat. Protoc. 2022;17(1):95–128. doi: 10.1038/s41596-021-00635-w. [DOI] [PubMed] [Google Scholar]
  68. Han E.L., Padilla M.S., Palanki R., Kim D., Mrksich K., Li J.J., Tang S., Yoon I.C., Mitchell M.J. Predictive high-throughput platform for dual screening of mRNA lipid nanoparticle blood-brain barrier transfection and crossing. Nano Lett. 2024;24(5):1477–1486. doi: 10.1021/acs.nanolett.3c03509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Han L., Jiang C. Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies. Acta Pharm. Sin. B. 2021;11(8):2306–2325. doi: 10.1016/j.apsb.2020.11.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Hannon G., Bogdanska A., Keogh A., Finn S.P., Gobbo O.L., Prina-Mello A. Biodistribution and histological analysis of iron oxide-dextran nanoparticles in wistar rats. Nanotoxicology. 2023;17(8-9):562–580. doi: 10.1080/17435390.2023.2276413. [DOI] [PubMed] [Google Scholar]
  71. Harding I.C., O'Hare N.R., Vigliotti M., Caraballo A., Lee C.I., Millican K., Herman I.M., Ebong E.E. Developing a transwell millifluidic device for studying blood-brain barrier endothelium. Lab Chip. 2022;22(23):4603–4620. doi: 10.1039/d2lc00657j. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Hasan S., Mahmud Z., Hossain M., Islam S. Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy. Mol. Biol. Rep. 2024;51(1):1069 doi: 10.1007/s11033-024-09996-3. [DOI] [PubMed] [Google Scholar]
  73. Hausmann D., Hoffmann D.C., Venkataramani V., Jung E., Horschitz S., Tetzlaff S.K., Jabali A., Hai L., Kessler T., Azoŕin D.D., Weil S., Kourtesakis A., Sievers P., Habel A., Breckwoldt M.O., Karreman M.A., Ratliff M., Messmer J.M., Yang Y., Reyhan E., Wendler S., Löb C., Mayer C., Figarella K., Osswald M., Solecki G., Sahm F., Garaschuk O., Kuner T., Koch P., Schlesner M., Wick W., Winkler F. Autonomous rhythmic activity in glioma networks drives brain tumour growth. Nature. 2023;613(7942):179–186. doi: 10.1038/s41586-022-05520-4. [DOI] [PubMed] [Google Scholar]
  74. Helgudóttir S.S., Johnsen K.B., Routhe L.G., Rasmussen C.L.M., Thomsen M.S., Moos T. Upregulation of transferrin receptor 1 (TfR1) but not glucose transporter 1 (GLUT1) or CD98hc at the blood-brain barrier in response to valproic acid. Cells. 2024;13(14):1181. doi: 10.3390/cells13141181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Hollmann E.K., Bailey A.K., Potharazu A.V., Neely M.D., Bowman A.B., Lippmann E.S. Accelerated differentiation of human induced pluripotent stem cells to blood-brain barrier endothelial cells. Fluids Barriers CNS. 2017;14(1):9. doi: 10.1186/s12987-017-0059-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Hopf N.B., Suter-Dick L., Huwyler J., Borgatta M., Hegg L., Pamies D., Paschoud H., Puligilla R.D., Reale E., Werner S., Zurich M.G. Novel strategy to assess the neurotoxicity of organic solvents such as glycol ethers: protocol for combining in vitro and in silico methods with human-controlled exposure experiments. JMIR Res. Protoc. 2024;13 doi: 10.2196/50300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Hori T., Okae H., Shibata S., Kobayashi N., Kobayashi E.H., Oike A., Sekiya A., Arima T., Kaji H. Trophoblast stem cell-based organoid models of the human placental barrier. Nat. Commun. 2024;15(1):962. doi: 10.1038/s41467-024-45279-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Hudecz D., Khire T., Chung H.L., Adumeau L., Glavin D., Luke E., Nielsen M.S., Dawson K.A., McGrath J.L., Yan Y. Ultrathin silicon membranes for in situ optical analysis of nanoparticle translocation across a human blood-brain barrier model. ACS Nano. 2020;14(1):1111–1122. doi: 10.1021/acsnano.9b08870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Hudson N., Campbell M. Tight junctions of the neurovascular unit. Front. Mol. Neurosci. 2021;14 doi: 10.3389/fnmol.2021.752781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Hwang D.G., Choi Y.M., Jang J. 3D bioprinting-based vascularized tissue models mimicking tissue-specific architecture and pathophysiology for in vitro studies. Front. Bioeng. Biotechnol. 2021;9 doi: 10.3389/fbioe.2021.685507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Isogai R., Morio H., Okamoto A., Kitamura K., Furihata T. Generation of a human conditionally immortalized cell-based multicellular spheroidal blood-brain barrier model for permeability evaluation of macromolecules. Bio-Protoc. 2022;12(15) doi: 10.21769/BioProtoc.4465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Ito T., Ota T., Kono R., Miyaoka Y., Ishibashi H., Komori M., Yasukawa A., Kanno Y., Miki N. Pump-free microfluidic hemofiltration device. Micromachines (Basel) 2021;12(8):992. doi: 10.3390/mi12080992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Jacob F., Salinas R.D., Zhang D.Y., Nguyen P.T.T., Schnoll J.G., Wong S.Z.H., Thokala R., Sheikh S., Saxena D., Prokop S., Liu D.A., Qian X., Petrov D., Lucas T., Chen H.I., Dorsey J.F., Christian K.M., Binder Z.A., Nasrallah M., Brem S., O'Rourke D.M., Ming G.L., Song H. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell. 2020;180(1):188–204.e22. doi: 10.1016/j.cell.2019.11.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Jain A., Bhise K. Nano-pharmacokinetics and pharmacodynamics of green-synthesized ZnO nanoparticles: a pathway to safer therapeutic applications. Xenobiotica. 2025;55(4):265–276. doi: 10.1080/00498254.2025.2505062. [DOI] [PubMed] [Google Scholar]
  85. Jeong M.H., Kim I., Park K., Ku B., Lee D.W., Park K.R., Jeon S.Y., Kim J.E. An automated high-throughput screening (HTS) spotter for 3D tumor spheroid formation. Int. J. Mol. Sci. 2023;24(2):1006. doi: 10.3390/ijms24021006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Jezierski A., Huang J., Haqqani A.S., Haukenfrers J., Liu Z., Baumann E., Sodja C., Charlebois C., Delaney C.E., Star A.T., Liu Q., Stanimirovic D.B. Mouse embryonic stem cell-derived blood-brain barrier model: applicability to studying antibody triggered receptor mediated transcytosis. Fluids Barriers CNS. 2023;20(1):36. doi: 10.1186/s12987-023-00437-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Kadry H., Cucullo L. Evaluation of barrier integrity using a two-layered microfluidic device mimicking the blood-brain barrier. Methods Mol. Biol. 2024;2711:77–88. doi: 10.1007/978-1-0716-3429-5_7. [DOI] [PubMed] [Google Scholar]
  88. Katt M.E., Shusta E.V. In vitro models of the blood-brain barrier: building in physiological complexity. Curr. Opin. Chem. Eng. 2020;30:42–52. doi: 10.1016/j.coche.2020.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Kawakita S., Mandal K., Mou L., Mecwan M.M., Zhu Y., Li S., Sharma S., Hernandez A.L., Nguyen H.T., Maity S., de Barros N.R., Nakayama A., Bandaru P., Ahadian S., Kim H.J., Herculano R.D., Holler E., Jucaud V., Dokmeci M.R., Khademhosseini A. Organ-on-a-chip models of the blood-brain barrier: recent advances and future prospects. Small. 2022;18(39) doi: 10.1002/smll.202201401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Kęska A. The actual toxicity of engine exhaust gases emitted from vehicles: the development and perspectives of biological and chemical measurement methods. ACS Omega. 2023;8(28):24718–24726. doi: 10.1021/acsomega.3c02171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Khare P., Edgecomb S.X., Hamadani C.M., Tanner E.E.L., Manickam S., D. Lipid nanoparticle-mediated drug delivery to the brain. Adv. Drug Deliv. Rev. 2023;197 doi: 10.1016/j.addr.2023.114861. [DOI] [PubMed] [Google Scholar]
  92. Khoonkari M., Liang D., Kamperman M., Kruyt F.A.E., van Rijn P. Physics of brain cancer: multiscale alterations of glioblastoma cells under extracellular matrix stiffening. Pharmaceutics. 2022;14(5):1031. doi: 10.3390/pharmaceutics14051031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Khosla K., Naus C.C., Sin W.C. Cx43 in neural progenitors promotes glioma invasion in a 3D culture system. Int. J. Mol. Sci. 2020;21(15):5216. doi: 10.3390/ijms21155216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Kim J., Shin S.A., Lee C.S., Chung H.J. An improved in vitro blood-brain barrier model for the evaluation of drug permeability using transwell with shear stress. Pharmaceutics. 2023;16(1):48. doi: 10.3390/pharmaceutics16010048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Kim S., Min S., Choi Y.S., Jo S.H., Jung J.H., Han K., Kim J., An S., Ji Y.W., Kim Y.G., Cho S.W. Tissue extracellular matrix hydrogels as alternatives to matrigel for culturing gastrointestinal organoids. Nat. Commun. 2022;13(1):1692. doi: 10.1038/s41467-022-29279-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Koh I., Hagiwara M. Modular tissue-in-a-CUBE platform to model blood-brain barrier (BBB) and brain interaction. Commun. Biol. 2024;7(1):177. doi: 10.1038/s42003-024-05857-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Koh I., Hagiwara M. Modular tissue-in-a-CUBE platform to model blood-brain barrier (BBB) and brain interaction. Commun. Biol. 2024;7(1):177. doi: 10.1038/s42003-024-05857-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Kondapaneni R.V., Gurung S.K., Nakod P.S., Goodarzi K., Yakati V., Lenart N.A., Rao S.S. Glioblastoma mechanobiology at multiple length scales. Biomater. Adv. 2024;160 doi: 10.1016/j.bioadv.2024.213860. [DOI] [PubMed] [Google Scholar]
  99. Kondapaneni R.V., Gurung S.K., Nakod P.S., Goodarzi K., Yakati V., Lenart N.A., Rao S.S. Glioblastoma mechanobiology at multiple length scales. Biomater. Adv. 2024;160 doi: 10.1016/j.bioadv.2024.213860. [DOI] [PubMed] [Google Scholar]
  100. Kopatz V., Wen K., Kovács T., Keimowitz A.S., Pichler V., Widder J., Vethaak A.D., Hollóczki O., Kenner L. Micro- and nanoplastics breach the blood-brain barrier (BBB): biomolecular corona's role revealed. Nanomaterials (Basel) 2023;13(8):1404. doi: 10.3390/nano13081404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Kurmann L., Okoniewski M., Ogunshola O.O., Leeners B., Imthurn B., Dubey R.K. Transcryptomic analysis of human brain-microvascular endothelial response to -pericytes: cell orientation defines barrier function. Cells. 2021;10(4):963. doi: 10.3390/cells10040963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Lah T.T., Novak M., Breznik B. Brain malignancies: glioblastoma and brain metastases. Semin. Cancer Biol. 2020;60:262–273. doi: 10.1016/j.semcancer.2019.10.010. [DOI] [PubMed] [Google Scholar]
  103. Lah T.T., Novak M., Breznik B. Brain malignancies: glioblastoma and brain metastases. Semin. Cancer Biol. 2020;60:262–273. doi: 10.1016/j.semcancer.2019.10.010. [DOI] [PubMed] [Google Scholar]
  104. Lam D., Enright H.A., Peters S.K.G., Moya M.L., Soscia D.A., Cadena J., Alvarado J.A., Kulp K.S., Wheeler E.K., Fischer N.O. Optimizing cell encapsulation condition in ECM-Collagen I hydrogels to support 3D neuronal cultures. J. Neurosci. Methods. 2020;329 doi: 10.1016/j.jneumeth.2019.108460. [DOI] [PubMed] [Google Scholar]
  105. Le T.H., Phan A.H.T., Le K.C.M., Phan T.D.U., Nguyen K.T. Utilizing polymer-conjugate albumin-based ultrafine gas bubbles in combination with ultra-high frequency radiations in drug transportation and delivery. RSC Adv. 2021;11(55):34440–34448. doi: 10.1039/d1ra04983f. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Lee S., Chung M., Jeon N.L. BBB-on-a-chip: modeling functional human blood-brain barrier by mimicking 3D brain angiogenesis using microfluidic chip. Methods Mol. Biol. 2022;2492:251–263. doi: 10.1007/978-1-0716-2289-6_14. [DOI] [PubMed] [Google Scholar]
  107. Lee S., Kim S., Ahn J., Park J., Ryu B.Y., Park J.Y. Membrane-bottomed microwell array added to transwell insert to facilitate non-contact co-culture of spermatogonial stem cell and STO feeder cell. Biofabrication. 2020;12(4) doi: 10.1088/1758-5090/abb529. [DOI] [PubMed] [Google Scholar]
  108. Lee W.Y., Yoon B.W. Brain-only metastasis and 10-year survival after curative gastric cancer resection: a case report. Case Rep. Oncol. 2023;16(1):204–209. doi: 10.1159/000530109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Leite P.E.C., Pereira M.R., Harris G., Pamies D., Dos Santos L.M.G., Granjeiro J.M., Hogberg H.T., Hartung T., Smirnova L. Suitability of 3D human brain spheroid models to distinguish toxic effects of gold and poly-lactic acid nanoparticles to assess biocompatibility for brain drug delivery. Part. Fibre Toxicol. 2019;16(1):22. doi: 10.1186/s12989-019-0307-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Li J., Wang Y., Xu C., Yu Q., Wang X., Xie H., Tian L., Qiu Y., Guo R., Lu Z., Li M., He Q. Rapid pH-responsive self-disintegrating nanoassemblies balance tumor accumulation and penetration for enhanced anti-breast cancer therapy. Acta Biomater. 2021;134:546–558. doi: 10.1016/j.actbio.2021.04.022. [DOI] [PubMed] [Google Scholar]
  111. Li Y., Terstappen G.C., Zhang W. Differentiation of human induced pluripotent stem cells (hiPSC) into endothelial-type cells and establishment of an in vitro blood-brain barrier model. Methods Mol. Biol. 2022;2454:521–530. doi: 10.1007/7651_2021_363. [DOI] [PubMed] [Google Scholar]
  112. Liang Y., Iqbal Z., Lu J., Wang J., Zhang H., Chen X., Duan L., Xia J. Cell-derived nanovesicle-mediated drug delivery to the brain: principles and strategies for vesicle engineering. Mol. Ther. 2023;31(5):1207–1224. doi: 10.1016/j.ymthe.2022.10.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Lim J., Fang H.W., Bupphathong S., Sung P.C., Yeh C.E., Huang W., Lin C.H. The edifice of vasculature-on-chips: a focused review on the key elements and assembly of angiogenesis models. ACS Biomater. Sci. Eng. 2024;10(6):3548–3567. doi: 10.1021/acsbiomaterials.3c01978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Lin Z., Sur S., Liu P., Li Y., Jiang D., Hou X., Darrow J., Pillai J.J., Yasar S., Rosenberg P., Albert M., Moghekar A., Lu H. Blood-brain barrier breakdown in relationship to Alzheimer and vascular disease. Ann. Neurol. 2021;90(2):227–238. doi: 10.1002/ana.26134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Liu D., Langston J.C., Prabhakarpandian B., Kiani M.F., Kilpatrick L.E. The critical role of neutrophil-endothelial cell interactions in sepsis: new synergistic approaches employing organ-on-chip, omics, immune cell phenotyping and in silico modeling to identify new therapeutics. Front. Cell. Infect. Microbiol. 2024;13:1274842. doi: 10.3389/fcimb.2023.1274842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Liu J., Teng P.Y., Kim W.K., Applegate T.J. Assay considerations for fluorescein isothiocyanate-dextran (FITC-d): an indicator of intestinal permeability in broiler chickens. Poult. Sci. 2021;100(7) doi: 10.1016/j.psj.2021.101202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Logsdon A.F., Rhea E.M., Reed M., Banks W.A., Erickson M.A. The neurovascular extracellular matrix in health and disease. Exp. Biol. Med. (Maywood) 2021;246(7):835–844. doi: 10.1177/1535370220977195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Lucero R., Zappulli V., Sammarco A., Murillo O.D., Cheah P.S., Srinivasan S., Tai E., Ting D.T., Wei Z., Roth M.E., Laurent L.C., Krichevsky A.M., Breakefield X.O., Milosavljevic A. Glioma-derived miRNA-containing extracellular vesicles induce angiogenesis by reprogramming brain endothelial cells. Cell Rep. 2020;30(7):2065–2074.e4. doi: 10.1016/j.celrep.2020.01.073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Madani F., Morovvati H., Webster T.J., Najaf Asaadi S., Rezayat S.M., Hadjighassem M., Khosravani M., Adabi M. Combination chemotherapy via poloxamer 188 surface-modified PLGA nanoparticles that traverse the blood-brain-barrier in a glioblastoma model. Sci. Rep. 2024;14(1):19516. doi: 10.1038/s41598-024-69888-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Mai-Morente S., Isasi E., Rafael A., Budelli G., Olivera-Bravo S., Vitureira N., Abudara V. Pericyte pannexin1 controls cerebral capillary diameter and supports memory function. Nat. Commun. 2025;16(1):6128. doi: 10.1038/s41467-025-61312-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Mao M., Wu Y., He Q. Recent advances in targeted drug delivery for the treatment of glioblastoma. Nanoscale. 2024;16(18):8689–8707. doi: 10.1039/d4nr01056f. [DOI] [PubMed] [Google Scholar]
  122. Marino A., Battaglini M., Lefevre M.C., Ceccarelli M.C., Ziaja K., Ciofani G. Sensorization of microfluidic brain-on-a-chip devices: towards a new generation of integrated drug screening systems. Trends Anal. Chem. 2023;168 doi: 10.1016/j.trac.2023.117319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Mármol I., Abizanda-Campo S., Ayuso J.M., Ochoa I., Oliván S. Towards novel biomimetic in vitro models of the blood-brain barrier for drug permeability evaluation. Bioengineering (Basel) 2023;10(5):572. doi: 10.3390/bioengineering10050572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Mauri E., Veglianese P., Papa S., Rossetti A., De Paola M., Mariani A., Posel Z., Posocco P., Sacchetti A., Rossi F. Effects of primary amine-based coatings on microglia internalization of nanogels. Colloids Surf. B: Biointerfaces. 2020;185 doi: 10.1016/j.colsurfb.2019.110574. [DOI] [PubMed] [Google Scholar]
  125. Mazurskyy A., Howitt J. Extracellular vesicles in neurological disorders. Subcell. Biochem. 2021;97:411–436. doi: 10.1007/978-3-030-67171-6_16. [DOI] [PubMed] [Google Scholar]
  126. McConnell H.L., Mishra A. Cells of the blood-brain barrier: an overview of the neurovascular unit in health and disease. Methods Mol. Biol. 2022;2492:3–24. doi: 10.1007/978-1-0716-2289-6_1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Mencattini A., Curci G., Riccardi A., Casti P., D'Orazio M., Filippi J., Antonelli G., Debbi E., Daprati E., Zhang W., Meng Q., Martinelli E. MEA-based graph deviation network for early Autism syndrome signatures in human forebrain organoids. Cyborg Bionic Syst. 2025;6:0441. doi: 10.34133/cbsystems.0441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Meng L., Wang C., Lu Y., Sheng G., Yang L., Wu Z., Xu H., Han C., Lu Y., Han F. Targeted regulation of blood-brain barrier for enhanced therapeutic efficiency of hypoxia-modifier nanoparticles and immune checkpoint blockade antibodies for glioblastoma. ACS Appl. Mater. Interfaces. 2021;13(10):11657–11671. doi: 10.1021/acsami.1c00347. [DOI] [PubMed] [Google Scholar]
  129. Merolle M., Mongiardi M.P., Piras M., Levi A., Falchetti M.L. Glioblastoma cells do not affect axitinib-dependent senescence of HUVECs in a transwell coculture model. Int. J. Mol. Sci. 2020;21(4):1490. doi: 10.3390/ijms21041490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Mineiro R., Albuquerque T., Neves A.R., Santos C.R.A., Costa D., Quintela T. The role of biological rhythms in new drug formulations to cross the brain barriers. Int. J. Mol. Sci. 2023;24(16):12541. doi: 10.3390/ijms241612541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Misawa N., Honda S. Increased sodium fluorescein transport by corticosteroids is inhibited by a LAT-1 specific inhibitor in retinal pigment epithelial cells in vitro. Sci. Rep. 2023;13(1):22981. doi: 10.1038/s41598-023-50196-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Mishra G., Awasthi R., Mishra S.K., Singh A.K., Tiwari A.K., Singh S.K., Nandi M.K. Development of epigallocatechin and ascorbic acid dual delivery transferosomes for managing Alzheimer's disease: in vitro and in vivo studies. ACS Omega. 2024;9(33):35463–35474. doi: 10.1021/acsomega.4c02140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Mohi-Ud-Din R., Mir R.H., Mir P.A., Banday N., Shah A.J., Sawhney G., Bhat M.M., Batiha G.E., Pottoo F.H. Dysfunction of ABC transporters at the surface of BBB: potential implications in intractable epilepsy and applications of nanotechnology enabled drug delivery. Curr. Drug Metab. 2022;23(9):735–756. doi: 10.2174/1389200223666220817115003. [DOI] [PubMed] [Google Scholar]
  134. Mokoena X., Mabeta P., Cordier W., Flepisi B.T. Glioblastoma cells alter brain endothelial cell homeostasis and tight junction protein expression in vitro. J. Neuro-Oncol. 2025;171(2):443–453. doi: 10.1007/s11060-024-04870-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Monteiro A.R., Barbosa D.J., Remião F., Silva R. Co-culture models: key players in in vitro neurotoxicity, neurodegeneration and BBB modeling studies. Biomedicines. 2024;12(3):626. doi: 10.3390/biomedicines12030626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Mori A., Vermeer M., van den Broek L.J., Heijmans J., Nicolas A., Bouwhuis J., Burton T., Matsumura K., Ohashi K., Ito S., Kramer B. High-throughput bronchus-on-a-chip system for modeling the human bronchus. Sci. Rep. 2024;14(1):26248. doi: 10.1038/s41598-024-77665-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Mourtas S., Mavroidi B., Marazioti A., Kannavou M., Sagnou M., Pelecanou M., Antimisiaris S.G. Liposomes decorated with 2-(4'-Aminophenyl)benzothiazole effectively inhibit abeta(1-42) fibril formation and exhibit in vitro brain-targeting potential. Biomacromolecules. 2020;21(12):4685–4698. doi: 10.1021/acs.biomac.0c00811. [DOI] [PubMed] [Google Scholar]
  138. Musafargani S., Mishra S., Gulyás M., Mahalakshmi P., Archunan G., Padmanabhan P., Gulyás B. Blood brain barrier: a tissue engineered microfluidic chip. J. Neurosci. Methods. 2020;331 doi: 10.1016/j.jneumeth.2019.108525. [DOI] [PubMed] [Google Scholar]
  139. Muzzi L., Di Lisa D., Falappa M., Pepe S., Maccione A., Pastorino L., Martinoia S., Frega M. Human-derived cortical neurospheroids coupled to passive, high-density and 3D MEAs: a valid platform for functional tests. Bioengineering (Basel) 2023;10(4):449. doi: 10.3390/bioengineering10040449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Nahon D.M., Vila Cuenca M., van den Hil F.E., Hu M., de Korte T., Frimat J.P., van den Maagdenberg A.M.J.M., Mummery C.L., Orlova V.V. Self-assembling 3D vessel-on-chip model with hiPSC-derived astrocytes. Stem Cell Rep. 2024;19(7):946–956. doi: 10.1016/j.stemcr.2024.05.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Nahon D.M., Vila Cuenca M., van den Hil F.E., Hu M., de Korte T., Frimat J.P., van den Maagdenberg A.M.J.M., Mummery C.L., Orlova V.V. Self-assembling 3D vessel-on-chip model with hiPSC-derived astrocytes. Stem Cell Rep. 2024;19(7):946–956. doi: 10.1016/j.stemcr.2024.05.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Nazari H., Shrestha J., Naei V.Y., Bazaz S.R., Sabbagh M., Thiery J.P., Warkiani M.E. Advances in TEER measurements of biological barriers in microphysiological systems. Biosens. Bioelectron. 2023;234 doi: 10.1016/j.bios.2023.115355. [DOI] [PubMed] [Google Scholar]
  143. Nazari H., Shrestha J., Naei V.Y., Bazaz S.R., Sabbagh M., Thiery J.P., Warkiani M.E. Advances in TEER measurements of biological barriers in microphysiological systems. Biosens. Bioelectron. 2023;234 doi: 10.1016/j.bios.2023.115355. [DOI] [PubMed] [Google Scholar]
  144. Nelson M.T., Charbonneau M.R., Coia H.G., Castillo M.J., Holt C., Greenwood E.S., Robinson P.J., Merrill E.A., Lubkowicz D., Mauzy C.A. Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip. Nat. Commun. 2021;12(1):2805. doi: 10.1038/s41467-021-23072-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Neumaier F., Zlatopolskiy B.D., Neumaier B. Drug penetration into the central nervous system: pharmacokinetic concepts and in vitro model systems. Pharmaceutics. 2021;13(10):1542. doi: 10.3390/pharmaceutics13101542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Noorani B., Chowdhury E.A., Alqahtani F., Ahn Y., Patel D., Al-Ahmad A., Mehvar R., Bickel U. LC-MS/MS-based in vitro and in vivo investigation of blood-brain barrier integrity by simultaneous quantitation of mannitol and sucrose. Fluids Barriers CNS. 2020;17(1):61. doi: 10.1186/s12987-020-00224-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Norouzi M., Yathindranath V., Thliveris J.A., Kopec B.M., Siahaan T.J., Miller D.W. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles. Sci. Rep. 2020;10(1):11292. doi: 10.1038/s41598-020-68017-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Okano H., Morimoto S. iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders. Cell Stem Cell. 2022;29(2):189–208. doi: 10.1016/j.stem.2022.01.007. [DOI] [PubMed] [Google Scholar]
  149. Oldak B., Wildschutz E., Bondarenko V., Comar M.Y., Zhao C., Aguilera-Castrejon A., Tarazi S., Viukov S., Pham T.X.A., Ashouokhi S., Lokshtanov D., Roncato F., Ariel E., Rose M., Livnat N., Shani T., Joubran C., Cohen R., Addadi Y., Chemla M., Kedmi M., Keren-Shaul H., Pasque V., Petropoulos S., Lanner F., Novershtern N., Hanna J.H. Complete human day 14 post-implantation embryo models from naive ES cells. Nature. 2023;622(7983):562–573. doi: 10.1038/s41586-023-06604-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Otter M., Csader S., Keiser M., Oswald S. Expression and functional contribution of different organic cation transporters to the cellular uptake of doxorubicin into human breast cancer and cardiac tissue. Int. J. Mol. Sci. 2021;23(1):255. doi: 10.3390/ijms23010255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  151. Ouyang X., Liu Y., Zheng K., Pang Z., Peng S. Recent advances in zwitterionic nanoscale drug delivery systems to overcome biological barriers.Asian. J. Pharm. Sci. 2024;19(1) doi: 10.1016/j.ajps.2023.100883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Ozgür B., Helms H.C.C., Tornabene E., Brodin B. Hypoxia increases expression of selected blood-brain barrier transporters GLUT-1, P-gp, SLC7A5 and TFRC, while maintaining barrier integrity, in brain capillary endothelial monolayers. Fluids Barriers CNS. 2022;19(1):1. doi: 10.1186/s12987-021-00297-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  153. Palma-Florez S., López-Canosa A., Moralez-Zavala F., Castaño O., Kogan M.J., Samitier J., Lagunas A., Mir M. BBB-on-a-chip with integrated micro-TEER for permeability evaluation of multi-functionalized gold nanorods against Alzheimer's disease. J. Nanobiotechnol. 2023;21(1):115. doi: 10.1186/s12951-023-01798-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  154. Palma-Florez S., López-Canosa A., Moralez-Zavala F., Castaño O., Kogan M.J., Samitier J., Lagunas A., Mir M. BBB-on-a-chip with integrated micro-TEER for permeability evaluation of multi-functionalized gold nanorods against Alzheimer's disease. J. Nanobiotechnol. 2023;21(1):115. doi: 10.1186/s12951-023-01798-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Pasupuleti V., Vora L., Prasad R., Nandakumar D.N., Khatri D.K. Glioblastoma preclinical models: strengths and weaknesses. Biochim. Biophys. Acta Rev. Cancer. 2024;1879(1) doi: 10.1016/j.bbcan.2023.189059. [DOI] [PubMed] [Google Scholar]
  156. Patient J.D., Hajiali H., Harris K., Abrahamsson B., Tannergren C., White L.J., Ghaemmaghami A.M., Williams P.M., Roberts C.J., Rose F.R.A.J. Nanofibrous scaffolds support a 3D in vitro permeability model of the human intestinal epithelium. Front. Pharmacol. 2019;10:456. doi: 10.3389/fphar.2019.00456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  157. Perrone M.G., Ruggiero A., Centonze A., Carrieri A., Ferorelli S., Scilimati A. Diffuse intrinsic pontine glioma (DIPG): breakthrough and clinical perspective. Curr. Med. Chem. 2021;28(17):3287–3317. doi: 10.2174/0929867327666200806110206. [DOI] [PubMed] [Google Scholar]
  158. Pfau S.J., Langen U.H., Fisher T.M., Prakash I., Nagpurwala F., Lozoya R.A., Lee W.A., Wu Z., Gu C. Characteristics of blood-brain barrier heterogeneity between brain regions revealed by profiling vascular and perivascular cells. Nat. Neurosci. 2024;27(10):1892–1903. doi: 10.1038/s41593-024-01743-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  159. Pfau S.J., Langen U.H., Fisher T.M., Prakash I., Nagpurwala F., Lozoya R.A., Lee W.A., Wu Z., Gu C. Characteristics of blood-brain barrier heterogeneity between brain regions revealed by profiling vascular and perivascular cells. Nat. Neurosci. 2024;27(10):1892–1903. doi: 10.1038/s41593-024-01743-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Piantino M., Figarol A., Matsusaki M. Three-dimensional in vitro models of healthy and tumor brain microvasculature for drug and toxicity screening. Front. Toxicol. 2021;3 doi: 10.3389/ftox.2021.656254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  161. Pierson Smela M.D., Kramme C.C., Fortuna P.R.J., Adams J.L., Su R., Dong E., Kobayashi M., Brixi G., Kavirayuni V.S., Tysinger E., Kohman R.E., Shioda T., Chatterjee P., Church G.M. Directed differentiation of human iPSCs to functional ovarian granulosa-like cells via transcription factor overexpression. Elife. 2023;12 doi: 10.7554/eLife.83291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  162. Pinto-Fraga J., García-Chico C., Lista S., Lacal P.M., Carpenzano G., Salvati M., Santos-Lozano A., Graziani G., Ceci C. protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials. Pharmacol. Res. 2024;107528 doi: 10.1016/j.phrs.2024.107528. [DOI] [PubMed] [Google Scholar]
  163. Pinto-Fraga J., García-Chico C., Lista S., Lacal P.M., Carpenzano G., Salvati M., Santos-Lozano A., Graziani G., Ceci C. Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials. Pharmacol. Res. 2025;212 doi: 10.1016/j.phrs.2024.107528. [DOI] [PubMed] [Google Scholar]
  164. Piras C.C., Smith D.K. Multicomponent polysaccharide alginate-based bioinks. J. Mater. Chem. B. 2020;8(36):8171–8188. doi: 10.1039/d0tb01005g. [DOI] [PubMed] [Google Scholar]
  165. Pizzocri M., Re F., Stanzani E., Formicola B., Tamborini M., Lauranzano E., Ungaro F., Rodighiero S., Francolini M., Gregori M., Perin A., DiMeco F., Masserini M., Matteoli M., Passoni L. Radiation and adjuvant drug-loaded liposomes target glioblastoma stem cells and trigger in-situ immune response. Neurooncol. Adv. 2021;3(1) doi: 10.1093/noajnl/vdab076. vdab076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  166. Prahl L.S., Stanslaski M.R., Vargas P., Piel M., Odde D.J. Predicting confined 1D cell migration from parameters calibrated to a 2D motor-clutch model. Biophys. J. 2020;118(7):1709–1720. doi: 10.1016/j.bpj.2020.01.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Pun S., Prakash A., Demaree D., Krummel D.P., Sciumè G., Sengupta S., Barrile R. Rapid biofabrication of an advanced microphysiological system mimicking phenotypical heterogeneity and drug resistance in glioblastoma. Adv. Healthc. Mater. 2024;13(30) doi: 10.1002/adhm.202401876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Qi D., Lin H., Hu B., Wei Y. A review on in vitro model of the blood-brain barrier (BBB) based on hCMEC/D3 cells. J. Control. Release. 2023;358:78–97. doi: 10.1016/j.jconrel.2023.04.020. [DOI] [PubMed] [Google Scholar]
  169. Qi D., Wu S., Lin H., Kuss M.A., Lei Y., Krasnoslobodtsev A., Ahmed S., Zhang C., Kim H.J., Jiang P., Duan B. Establishment of a human iPSC- and nanofiber-based microphysiological blood-brain barrier system. ACS Appl. Mater. Interfaces. 2018;10(26):21825–21835. doi: 10.1021/acsami.8b03962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Qiu Y.M., Zhang C.L., Chen A.Q., Wang H.L., Zhou Y.F., Li Y.N., Hu B. Immune cells in the BBB disruption after acute ischemic stroke: targets for immune therapy? Front. Immunol. 2021;12 doi: 10.3389/fimmu.2021.678744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  171. Raghav M., Gupta V., Awasthi R., Singh A., Kulkarni G.T. Nose-to-brain drug delivery: challenges and progress towards brain targeting in the treatment of neurological disorders. J. Drug Delivery Sci. Technol. 2023;86 [Google Scholar]
  172. Rauth S., Karmakar S., Batra S.K., Ponnusamy M.P. Recent advances in organoid development and applications in disease modeling. Biochim. Biophys. Acta Rev. Cancer. 2021;1875(2) doi: 10.1016/j.bbcan.2021.188527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  173. Rawat A., Morrison B.M. Metabolic transporters in the peripheral nerve-what, where, and why? Neurotherapeutics. 2021;18(4):2185–2199. doi: 10.1007/s13311-021-01150-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  174. Robert J., Weilinger N.L., Cao L.P., Cataldi S., Button E.B., Stukas S., Martin E.M., Seibler P., Gilmour M., Caffrey T.M., Rowe E.M., Fan J., MacVicar B., Farrer M.J., Wellington C.L. An in vitro bioengineered model of the human arterial neurovascular unit to study neurodegenerative diseases. Mol. Neurodegener. 2020;15(1):70. doi: 10.1186/s13024-020-00418-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  175. Roghani A.K., Garcia R.I., Roghani A., Reddy A., Khemka S., Reddy R.P., Pattoor V., Jacob M., Reddy P.H., Sehar U. Treating Alzheimer's disease using nanoparticle-mediated drug delivery strategies/systems. Ageing Res. Rev. 2024;97 doi: 10.1016/j.arr.2024.102291. [DOI] [PubMed] [Google Scholar]
  176. Ronaldson P.T., Davis T.P. Transport mechanisms at the blood-brain barrier and in cellular compartments of the neurovascular unit: focus on CNS delivery of small molecule drugs. Pharmaceutics. 2022;14(7):1501. doi: 10.3390/pharmaceutics14071501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  177. Rosowski S., Remmert C., Marder M., Akishiba M., Bushe J., Feuchtinger A., Platen A., Ussar S., Theis F., Wiedenmann S., Meier M. Single-cell characterization of neovascularization using hiPSC-derived endothelial cells in a 3D microenvironment. Stem Cell. Rep. 2023;18(10):1972–1986. doi: 10.1016/j.stemcr.2023.08.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  178. Ryu W.K., Cha H.K., Kim W., Lee H.Y., Kim H.J., Ryu J.S., Lim J.H. Effect of whole-brain radiotherapy with platinum-based chemotherapy in non-small cell lung cancer patients with multiple metastases including brain metastases. Sci. Rep. 2023;13(1):13173. doi: 10.1038/s41598-023-40235-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  179. Saleh M.A.A., Gülave B., Campagne O., Stewart C.F., Elassaiss-Schaap J., de Lange E.C.M. Using the LeiCNS-PK3.0 physiologically-based pharmacokinetic model to predict brain extracellular fluid pharmacokinetics in mice. Pharm. Res. 2023;40(11):2555–2566. doi: 10.1007/s11095-023-03554-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  180. Santillán-Cortez D., Castell-Rodríguez A.E., González-Arenas A., Suárez-Cuenca J.A., Pérez-Koldenkova V., Añorve-Bailón D., Toledo-Lozano C.G., García S., Escamilla-Tilch M., Mondragón-Terán P. A versatile microfluidic device system that lacks a synthetic extracellular matrix recapitulates the blood-brain barrier and dynamic tumor cell interaction. Bioengineering (Basel) 2024;11(10):1008. doi: 10.3390/bioengineering11101008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  181. Saylor D. Neurologic complications of tuberculosis. Continuum (Minneap Minn) 2021;27(4):992–1017. doi: 10.1212/CON.0000000000001005. [DOI] [PubMed] [Google Scholar]
  182. Schwake M., Müther M., Bruns A.K., Zinnhardt B., Warneke N., Holling M., Schipmann S., Brokinkel B., Wölfer J., Stummer W., Grauer O. Combined fluorescence-guided resection and intracavitary thermotherapy with superparamagnetic iron-oxide nanoparticles for recurrent high-grade glioma: case series with emphasis on complication management. Cancers (Basel) 2022;14(3):541. doi: 10.3390/cancers14030541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  183. Scioli Montoto S., Muraca G., Ruiz M.E. Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects. Front. Mol. Biosci. 2020;7 doi: 10.3389/fmolb.2020.587997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  184. Semyachkina-Glushkovskaya O., Terskov A., Khorovodov A., Telnova V., Blokhina I., Saranceva E., Kurths J. Photodynamic opening of the blood-brain barrier and the meningeal lymphatic system: the new niche in immunotherapy for brain tumors. Pharmaceutics. 2022;14(12):2612. doi: 10.3390/pharmaceutics14122612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  185. Serras A.S., Rodrigues J.S., Cipriano M., Rodrigues A.V., Oliveira N.G., Miranda J.P. A critical perspective on 3D liver models for drug metabolism and toxicology studies. Front. Cell Dev. Biol. 2021;9 doi: 10.3389/fcell.2021.626805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  186. Shao W., Meng W., Zuo J., Li X., Ming D. Opportunities and challenges of brain-on-a-chip interfaces. Cyborg Bionic Syst. 2025;6:0287. doi: 10.34133/cbsystems.0287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  187. Shen Z., Liu T., Yang Z., Zhou Z., Tang W., Fan W., Liu Y., Mu J., Li L., Bregadze V.I., Mandal S.K., Druzina A.A., Wei Z., Qiu X., Wu A., Chen X. Small-sized gadolinium oxide based nanoparticles for high-efficiency theranostics of orthotopic glioblastoma. Biomaterials. 2020;235 doi: 10.1016/j.biomaterials.2020.119783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  188. Sherman H., Rossi A.E. A novel three-dimensional glioma blood-brain barrier model for high-throughput testing of tumoricidal capability. Front. Oncol. 2019;9:351. doi: 10.3389/fonc.2019.00351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  189. Shi Y., He X., Wang H., Dai J., Fang J., He Y., Chen X., Hong Z., Chai Y. Construction of a novel blood brain barrier-glioma microfluidic chip model: applications in the evaluation of permeability and anti-glioma activity of traditional Chinese medicine components. Talanta. 2023;253 doi: 10.1016/j.talanta.2022.123971. [DOI] [PubMed] [Google Scholar]
  190. Shin W., Hinojosa C.D., Ingber D.E., Kim H.J. Human intestinal morphogenesis controlled by transepithelial morphogen gradient and flow-dependent physical cues in a microengineered gut-on-a-chip. iScience. 2019;15:391–406. doi: 10.1016/j.isci.2019.04.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  191. Shin W., Kim H.J. 3D in vitro morphogenesis of human intestinal epithelium in a gut-on-a-chip or a hybrid chip with a cell culture insert. Nat. Protoc. 2022;17(3):910–939. doi: 10.1038/s41596-021-00674-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  192. Shuchat S., Yossifon G., Huleihel M. Perfusion in organ-on-chip models and its applicability to the replication of spermatogenesis in vitro. Int. J. Mol. Sci. 2022;23(10):5402. doi: 10.3390/ijms23105402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  193. Singh A.K., Gothwal A., Rani S., Rana M., Sharma A.K., Yadav A.K., Gupta U. Dendrimer donepezil conjugates for improved brain delivery and better in vivo pharmacokinetics. ACS Omega. 2019;4:4519–4529. [Google Scholar]
  194. Singh A.K., Singh S., Minocha T., Yadav S.K., Narayan R., Nayak U.Y., Singh S.K., Awasthi R. In vitro profiling and molecular dynamics simulation studies of berberine loaded MCM-41 mesoporous silica nanoparticles to prevent neuronal apoptosis. Nanoscale Adv. 2024;6(9):2469–2486. doi: 10.1039/d3na01142a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  195. Singh Anurag Kumar, Singh Saumitra Sen, Rathore Aaina Singh, Singh Surya Pratap, Mishra Gaurav, Awasthi Rajendra, Mishra Sunil Kumar, Gautam Vibhav, Singh Santosh Kumar. Lipid-coated MCM-41 mesoporous silica nanoparticles loaded with berberine improved inhibition of acetylcholine esterase and amyloid formation. ACS Biomater. Sci. Eng. 2021;7(8):3737–3753. doi: 10.1021/acsbiomaterials.1c00514. [DOI] [PubMed] [Google Scholar]
  196. Sokolova V., Mekky G., van der Meer S.B., Seeds M.C., Atala A.J., Epple M. Transport of ultrasmall gold nanoparticles (2 nm) across the blood-brain barrier in a six-cell brain spheroid model. Sci. Rep. 2020;10(1):18033. doi: 10.1038/s41598-020-75125-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  197. Sokolova V., Mekky G., van der Meer S.B., Seeds M.C., Atala A.J., Epple M. Transport of ultrasmall gold nanoparticles (2 nm) across the blood-brain barrier in a six-cell brain spheroid model. Sci. Rep. 2020;10(1):18033. doi: 10.1038/s41598-020-75125-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  198. Soler Y., Rodriguez M., Austin D., Gineste C., Gelber C., El-Hage N. SERPIN-derived small peptide (SP16) as a potential therapeutic agent against HIV-Induced inflammatory molecules and viral replication in cells of the central nervous system. Cells. 2023;12(4):632. doi: 10.3390/cells12040632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  199. Soliman Y., Al-Khodor J., Yildirim Köken G., Mustafaoglu N. A guide for blood-brain barrier models. FEBS Lett. 2025;599(5):599–644. doi: 10.1002/1873-3468.15053. [DOI] [PubMed] [Google Scholar]
  200. Song Q., Li J., Li T., Li H.W. Nanomaterials that aid in the diagnosis and treatment of Alzheimer's disease, resolving blood-brain barrier crossing ability. Adv. Sci. (Weinh) 2024;11(38) doi: 10.1002/advs.202403473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  201. Sood A., Kumar A., Dev A., Gupta V.K., Han S.S. Advances in hydrogel-based microfluidic blood-brain-barrier models in oncology research. Pharmaceutics. 2022;14(5):993. doi: 10.3390/pharmaceutics14050993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  202. Stanton A.E., Bubnys A., Agbas E., James B., Park D.S., Jiang A., Pinals R.L., Liu L., Truong N., Loon A., Staab C., Cerit O., Wen H.L., Mankus D., Bisher M.E., Lytton-Jean A.K.R., Kellis M., Blanchard J.W., Langer R., Tsai L.H. Engineered 3D immuno-glial-neurovascular human miBrain model. Proc. Natl. Acad. Sci. USA. 2025;122(42) doi: 10.1073/pnas.2511596122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  203. Struth E., Labaf M., Karimnia V., Liu Y., Cramer G., Dahl J.B., Slack F.J., Zarringhalam K., Celli J.P. Drug resistant pancreatic cancer cells exhibit altered biophysical interactions with stromal fibroblasts in imaging studies of 3D co-culture models. Sci. Rep. 2024;14(1):20698. doi: 10.1038/s41598-024-71372-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  204. Sun J., Huang Y., Gong J., Wang J., Fan Y., Cai J., Wang Y., Qiu Y., Wei Y., Xiong C., Chen J., Wang B., Ma Y., Huang L., Chen X., Zheng S., Huang W., Ke Q., Wang T., Li X., Zhang W., Xiang A.P., Li W. Transplantation of hPSC-derived pericyte-like cells promotes functional recovery in ischemic stroke mice. Nat. Commun. 2020;11(1):5196. doi: 10.1038/s41467-020-19042-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  205. Szewczyk-Łagodzińska M., Plichta A., Dębowski M., Kowalczyk S., Iuliano A., Florjańczyk Z. Recent advances in the application of ATRP in the synthesis of drug delivery systems. Polymers (Basel) 2023;15(5):1234. doi: 10.3390/polym15051234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  206. Tang M., Rich J.N., Chen S. Biomaterials and 3D bioprinting strategies to model glioblastoma and the blood-brain barrier. Adv. Mater. 2021;33(5) doi: 10.1002/adma.202004776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  207. Tang X.Y., Wu S., Wang D., Chu C., Hong Y., Tao M., Hu H., Xu M., Guo X., Liu Y. Human organoids in basic research and clinical applications. Signal Transduct. Target. Ther. 2022;7(1):168. doi: 10.1038/s41392-022-01024-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  208. Tehrani S.F., Rabanel J.M., Legeay S., Cayon J., Riou J., Saulnier P., Marleau S., Roullin V.G., Hildgen P., Bastiat G. Tailoring PEGylated nanoparticle surface modulates inflammatory response in vascular endothelial cells. Eur. J. Pharm. Biopharm. 2022;174:155–166. doi: 10.1016/j.ejpb.2022.04.003. [DOI] [PubMed] [Google Scholar]
  209. Thombre R., Mess G., Kempski Leadingham K.M., Kapoor S., Hersh A., Acord M., Kaovasia T., Theodore N., Tyler B., Manbachi A. Towards standardization of the parameters for opening the blood-brain barrier with focused ultrasound to treat glioblastoma multiforme: a systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models. Front. Oncol. 2023;12:1072780. doi: 10.3389/fonc.2022.1072780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  210. Thomsen M.S., Humle N., Hede E., Moos T., Burkhart A., Thomsen L.B. The blood-brain barrier studied in vitro across species. PLoS One. 2021;16(3) doi: 10.1371/journal.pone.0236770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  211. Thomsen M.S., Johnsen K.B., Kucharz K., Lauritzen M., Moos T. Blood-brain barrier transport of transferrin receptor-targeted nanoparticles. Pharmaceutics. 2022;14(10):2237. doi: 10.3390/pharmaceutics14102237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  212. Tylawsky D.E., Kiguchi H., Vaynshteyn J., Gerwin J., Shah J., Islam T., Boyer J.A., Boué D.R., Snuderl M., Greenblatt M.B., Shamay Y., Raju G.P., Heller D.A. P-selectin-targeted nanocarriers induce active crossing of the blood-brain barrier via caveolin-1-dependent transcytosis. Nat. Mater. 2023;22(3):391–399. doi: 10.1038/s41563-023-01481-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  213. Tzng E., Bayardo N., Ikeda G., Vadgama N., Takashima H., Lyons J., Ieki H., Bennett M., Snyder M., Wu J.C., O'Brien C.G., Yang P.C. Molecular mechanisms of exosomes from human iPSC-cardiomyocytes and mesenchymal stem cells in restoring the injured myocardium. J. Am. Heart Assoc. 2025;14(21) doi: 10.1161/JAHA.124.037005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  214. Ubogu E.E. Biology of the human blood-nerve barrier in health and disease. Exp. Neurol. 2020;328 doi: 10.1016/j.expneurol.2020.113272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  215. Uchida Y. Quantitative proteomics-based blood-brain barrier study. Biol. Pharm. Bull. 2021;44(4):465–473. doi: 10.1248/bpb.b21-00001. [DOI] [PubMed] [Google Scholar]
  216. Upton D.H., Ung C., George S.M., Tsoli M., Kavallaris M., Ziegler D.S. Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy. Theranostics. 2022;12(10):4734–4752. doi: 10.7150/thno.69682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  217. Valadez-Barba V., Cota-Coronado A., Hernández-Pérez O.R., Lugo-Fabres P.H., Padilla-Camberos E., Díaz N.F., Díaz-Martínez N.E. iPSC for modeling neurodegenerative disorders. Regen. Ther. 2020;15:332–339. doi: 10.1016/j.reth.2020.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  218. Verma R., Rao L., Kumar H., Bansal N., Deep A., Parashar J., Yadav M., Mittal V., Kaushik D. Applications of nanomedicine in brain tumor therapy: nanocarrierbased drug delivery platforms, challenges, and perspectives. Rec. Pat. Nanotechnol. 2025;19(1):99–119. doi: 10.2174/0118722105244482231017102857. [DOI] [PubMed] [Google Scholar]
  219. Vetter J., Palagi I., Waisman A., Blaeser A. Recent advances in blood-brain barrier-on-a-chip models. Acta Biomater. 2025;197:1–28. doi: 10.1016/j.actbio.2025.03.041. [DOI] [PubMed] [Google Scholar]
  220. Vigh J.P., Kincses A., Ozgür B., Walter F.R., Santa-Maria A.R., Valkai S., Vastag M., Neuhaus W., Brodin B., Dér A., Deli M.A. Transendothelial electrical resistance measurement across the blood-brain barrier: a critical review of methods. Micromachines (Basel) 2021;12(6):685. doi: 10.3390/mi12060685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  221. Vo T.T.L., Shin D., Ha E., Seo J.H. Dysfunction of the neurovascular unit by psychostimulant drugs. Int. J. Mol. Sci. 2023;24(20):15154. doi: 10.3390/ijms242015154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  222. Wang H., Brown P.C., Chow E.C.Y., Ewart L., Ferguson S.S., Fitzpatrick S., Freedman B.S., Guo G.L., Hedrich W., Heyward S., Hickman J., Isoherranen N., Li A.P., Liu Q., Mumenthaler S.M., Polli J., Proctor W.R., Ribeiro A., Wang J.Y., Wange R.L., Huang S.M. 3D cell culture models: drug pharmacokinetics, safety assessment, and regulatory consideration. Clin. Transl. Sci. 2021;14(5):1659–1680. doi: 10.1111/cts.13066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  223. Wang J., Li Z., Pan M., Fiaz M., Hao Y., Yan Y., Sun L., Yan F. Ultrasound-mediated blood-brain barrier opening: an effective drug delivery system for theranostics of brain diseases. Adv. Drug Deliv. Rev. 2022;190 doi: 10.1016/j.addr.2022.114539. [DOI] [PubMed] [Google Scholar]
  224. Wang K., Man K., Liu J., Liu Y., Chen Q., Zhou Y., Yang Y. Microphysiological systems: design, fabrication, and applications. ACS Biomater. Sci. Eng. 2020;6(6):3231–3257. doi: 10.1021/acsbiomaterials.9b01667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  225. Wang M., Gage F.H., Schafer S.T. Transplantation strategies to enhance maturity and cellular complexity in brain organoids. Biol. Psychiatry. 2023;93(7):616–621. doi: 10.1016/j.biopsych.2023.01.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  226. Wang X., Hou Y., Ai X., Sun J., Xu B., Meng X., Zhang Y., Zhang S. Potential applications of microfluidics based blood brain barrier (BBB)-on-chips for in vitro drug development. Biomed. Pharmacother. 2020;132 doi: 10.1016/j.biopha.2020.110822. [DOI] [PubMed] [Google Scholar]
  227. Wang Y., Ma X., Qiao Z., Zhang X., Ji J., Zhang S., Zhuang W., Wu J., Li A., Wang C., Xiu X., Wang J., Meng Y., Huang W., Lang X., Liu X., Sun B., Li H., Liu Y. Electroacupuncture alleviates blood-brain barrier disruption and neuroinflammation via astrocytic MC4R in a mouse model of multiple sclerosis. J. Neuroinflammation. 2025;23(1):40. doi: 10.1186/s12974-025-03667-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  228. Wasielewska J.M., White A.R. Focused ultrasound-mediated drug delivery in humans - a path towards translation in neurodegenerative diseases. Pharm. Res. 2022;39(3):427–439. doi: 10.1007/s11095-022-03185-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  229. Watanabe D., Nakagawa S., Morofuji Y., Tóth A.E., Vastag M., Aruga J., Niwa M., Deli M.A. Characterization of a primate blood-brain barrier co-culture model prepared from primary brain endothelial cells, pericytes and astrocytes. Pharmaceutics. 2021;13(9):1484. doi: 10.3390/pharmaceutics13091484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  230. Watanabe M., Sudo R. Microfluidic device setting by coculturing endothelial cells and mesenchymal stem cells. Methods Mol. Biol. 2021;2206:57–66. doi: 10.1007/978-1-0716-0916-3_6. [DOI] [PubMed] [Google Scholar]
  231. Wen J., Liu F., Cheng Q., Weygant N., Liang X., Fan F., Li C., Zhang L., Liu Z. Applications of organoid technology to brain tumors. CNS Neurosci. Ther. 2023;29(10):2725–2743. doi: 10.1111/cns.14272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  232. Wen J., Liu F., Cheng Q., Weygant N., Liang X., Fan F., Li C., Zhang L., Liu Z. Applications of organoid technology to brain tumors. CNS Neurosci. Ther. 2023;29(10):2725–2743. doi: 10.1111/cns.14272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  233. Wevers N.R., Nair A.L., Fowke T.M., Pontier M., Kasi D.G., Spijkers X.M., Hallard C., Rabussier G., van Vught R., Vulto P., de Vries H.E., Lanz H.L. Modeling ischemic stroke in a triculture neurovascular unit on-a-chip. Fluids Barriers CNS. 2021;18(1):59. doi: 10.1186/s12987-021-00294-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  234. Wirsching H.G., Roth P., Weller M. A vasculature-centric approach to developing novel treatment options for glioblastoma. Expert Opin. Ther. Targets. 2021;25(2):87–100. doi: 10.1080/14728222.2021.1881062. [DOI] [PubMed] [Google Scholar]
  235. Workman M.J., Svendsen C.N. Recent advances in human iPSC-derived models of the blood-brain barrier. Fluids Barriers CNS. 2020;17(1):30. doi: 10.1186/s12987-020-00191-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  236. Xiang Y., Wang B., Yang W., Zheng X., Chen R., Gong Q., Gu Z., Liu Y., Luo K. Mitocytosis mediated by an enzyme-activable mitochondrion-disturbing polymer-drug conjugate enhances active penetration in glioblastoma therapy. Adv. Mater. 2024;36(18) doi: 10.1002/adma.202311500. [DOI] [PubMed] [Google Scholar]
  237. Xiao M., Xiao Z.J., Yang B., Lan Z., Fang F. Blood-brain barrier: more contributor to disruption of central nervous system homeostasis than victim in neurological disorders. Front. Neurosci. 2020;14:764. doi: 10.3389/fnins.2020.00764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  238. Xiao R., Ding J., Chen J., Zhao Z., He L., Wang H., Huang S., Luo B. Citric acid coated ultrasmall superparamagnetic iron oxide nanoparticles conjugated with lactoferrin for targeted negative MR imaging of glioma. J. Biomater. Appl. 2021;36(1):15–25. doi: 10.1177/0885328220975570. [DOI] [PubMed] [Google Scholar]
  239. Xiao R.R., Jing B., Yan L., Li J., Tu P., Ai X. Constant-rate perfused array chip for high-throughput screening of drug permeability through brain endothelium. Lab Chip. 2022;22(23):4481–4492. doi: 10.1039/d2lc00507g. [DOI] [PubMed] [Google Scholar]
  240. Xu M., Qin Z., Chen Z., Wang S., Peng L., Li X., Yuan Z. Nanorobots mediated drug delivery for brain cancer active targeting and controllable therapeutics. Discov. Nano. 2024;19(1):183. doi: 10.1186/s11671-024-04131-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  241. Xue J., Lin J., Liu Z., Zhang Q., Tang J., Han J., Wu S., Liu C., Zhao L., Li Y., Zhuo Y. Alleviating early demyelination in ischaemia/reperfusion by inhibiting sphingosine-1-phosphate receptor 2 could protect visual function from impairment. Brain Pathol. 2023;33(5) doi: 10.1111/bpa.13161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  242. Yadav N., Purow B.W. Understanding current experimental models of glioblastoma-brain microenvironment interactions. J. Neuro-Oncol. 2024;166(2):213–229. doi: 10.1007/s11060-023-04536-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  243. Yan L., Moriarty R.A., Stroka K.M. Recent progress and new challenges in modeling of human pluripotent stem cell-derived blood-brain barrier. Theranostics. 2021;11(20):10148–10170. doi: 10.7150/thno.63195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  244. Yan L., Moriarty R.A., Stroka K.M. Recent progress and new challenges in modeling of human pluripotent stem cell-derived blood-brain barrier. Theranostics. 2021;11(20):10148–10170. doi: 10.7150/thno.63195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  245. Yan L., Moriarty R.A., Stroka K.M. Recent progress and new challenges in modeling of human pluripotent stem cell-derived blood-brain barrier. Theranostics. 2021;11(20):10148–10170. doi: 10.7150/thno.63195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  246. Yan L., Moriarty R.A., Stroka K.M. Recent progress and new challenges in modeling of human pluripotent stem cell-derived blood-brain barrier. Theranostics. 2021;11(20):10148–10170. doi: 10.7150/thno.63195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  247. Yao M., Ventura P.B., Jiang Y., Rodriguez F.J., Wang L., Perry J.S.A., Yang Y., Wahl K., Crittenden R.B., Bennett M.L., Qi L., Gong C.C., Li X.N., Barres B.A., Bender T.P., Ravichandran K.S., Janes K.A., Eberhart C.G., Zong H. Astrocytic trans-differentiation completes a multicellular paracrine feedback loop required for medulloblastoma tumor growth. Cell. 2020;180(3):502–520.e19. doi: 10.1016/j.cell.2019.12.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  248. Yarygin K.N., Namestnikova D.D., Sukhinich K.K., Gubskiy I.L., Majouga A.G., Kholodenko I.V. Cell therapy of stroke: do the intra-arterially transplanted mesenchymal stem cells cross the blood-brain barrier? Cells. 2021;10(11):2997. doi: 10.3390/cells10112997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  249. Ye C., Li H., Li Y., Zhang Y., Liu G., Mi H., Li H., Xiao Q., Niu L., Yu X. Hypoxia-induced HMGB1 promotes glioma stem cells self-renewal and tumorigenicity via RAGE. iScience. 2022;25(9) doi: 10.1016/j.isci.2022.104872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  250. Yu F., Kumar N.D.S., Foo L.C., Ng S.H., Hunziker W., Choudhury D. A pump-free tricellular blood-brain barrier on-a-chip model to understand barrier property and evaluate drug response. Biotechnol. Bioeng. 2020;117(4):1127–1136. doi: 10.1002/bit.27260. [DOI] [PubMed] [Google Scholar]
  251. Zhang H., Huang N., Bian S., Sawan M. Platinum wire-embedded culturing device for interior signal recording from lollipop-shaped neural spheroids. Cyborg Bionic Syst. 2025;6:0220. doi: 10.34133/cbsystems.0220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  252. Zhang J.M., Ji Q., Duan H. Three-dimensional printed devices in droplet microfluidics. Micromachines (Basel) 2019;10(11):754. doi: 10.3390/mi10110754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  253. Zhang Y., Mu B.R., Ran Z., Zhu T., Huang X., Yang X., Wang D.M., Ma Q.H., Lu M.H. Pericytes in Alzheimer's disease: key players and therapeutic targets. Exp. Neurol. 2024;379 doi: 10.1016/j.expneurol.2024.114825. [DOI] [PubMed] [Google Scholar]
  254. Zhao Y., Gan L., Ren L., Lin Y., Ma C., Lin X. Factors influencing the blood-brain barrier permeability. Brain Res. 2022;1788 doi: 10.1016/j.brainres.2022.147937. [DOI] [PubMed] [Google Scholar]
  255. Zhao Y., Gan L., Ren L., Lin Y., Ma C., Lin X. Factors influencing the blood-brain barrier permeability. Brain Res. 2022;1788 doi: 10.1016/j.brainres.2022.147937. [DOI] [PubMed] [Google Scholar]
  256. Zhao Y., Gan L., Ren L., Lin Y., Ma C., Lin X. Factors influencing the blood-brain barrier permeability. Brain Res. 2022;1788 doi: 10.1016/j.brainres.2022.147937. [DOI] [PubMed] [Google Scholar]
  257. Zheng Z., Chopp M., Chen J. Multifaceted roles of pericytes in central nervous system homeostasis and disease. J. Cereb. Blood Flow Metab. 2020;40(7):1381–1401. doi: 10.1177/0271678X20911331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  258. Zhong X., Na Y., Yin S., Yan C., Gu J., Zhang N., Geng F. Cell membrane biomimetic nanoparticles with potential in treatment of Alzheimer's disease. Molecules. 2023;28(5):2336. doi: 10.3390/molecules28052336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  259. Zhou Q. Organizing the synaptic junctions. J. Biol. Chem. 2023;299(5) doi: 10.1016/j.jbc.2023.104716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  260. Zhu T., Hu Y., Cui H., Cui H. 3D multispheroid assembly strategies towards tissue engineering and disease modeling. Adv. Healthc. Mater. 2024;13(23) doi: 10.1002/adhm.202400957. [DOI] [PubMed] [Google Scholar]
  261. Zhuo W., Wang W., Zhou W., Duan Z., He S., Zhang X., Yi L., Zhang R., Guo A., Gou X., Chen J., Huang N., Sun X., Qian Z., Wang X., Gao X. A targeted and responsive nanoprodrug delivery system for synergistic glioma chemotherapy. Small. 2024;20(30) doi: 10.1002/smll.202400630. [DOI] [PubMed] [Google Scholar]
  262. Zierfuss B., Larochelle C., Prat A. Blood-brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies. Lancet Neurol. 2024;23(1):95–109. doi: 10.1016/S1474-4422(23)00377-0. [DOI] [PubMed] [Google Scholar]
  263. Zierfuss B., Larochelle C., Prat A. Blood-brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies. Lancet Neurol. 2024;23(1):95–109. doi: 10.1016/S1474-4422(23)00377-0. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data availability is not applicable to this review article as no new data were created or analyzed in this study.


Articles from International Journal of Pharmaceutics: X are provided here courtesy of Elsevier

RESOURCES